1
|
Garofalo M, Corsini A, Potena L, Schinzari M, Nardi E, Barberini F, Gargiulo C, Malaguti M, Sabatino M, Semprini F, Galie N, Nanni S. Clinical profile and in-hospital outcome of patients supported by intra-aortic balloon pump in the clinical setting of cardiogenic shock according to aetiology. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Despite controversial evidence, intra-aortic balloon pump (IABP) is still the most used temporary mechanical support in cardiogenic shock (CS), as a bridge to recovery or to more advanced mechanical support and/or heart transplantation [1]. Indeed, the available evidence, which is mainly restricted to the context of acute coronary syndromes (ACS) and is limited by the variability of CS definitions, shows no benefit in terms of mortality [2]. Randomized controlled trials on IABP in the setting of non-ACS CS are still missing. As a result, European guidelines do not recommend the routine use of IABP, which may be considered in refractory CS [3].
Purpose
The aim of our study was to analyse the use of IABP in the context of CS, providing insights into its indications, outcomes, and complications in relation to the aetiology (ACS vs non-ACS) of CS.
Methods
We retrospectively enrolled all consecutive adult patients receiving IABP for refractory CS at our tertiary referral Hospital between 2009 and 2018, and analysed data focusing on in-hospital outcomes, including death, recovery, heart transplantation, and escalation to more advanced mechanical support such as venoarterial extracorporeal membrane oxygenation (VA-ECMO) or left ventricular assist device (LVAD), and on IABP-related complications.
Results
403 patients received IABP, 75.2% (n=303) for ACS CS and 24.8% (n=100) for non-ACS CS. With respect to ACS patients, non-ACS patients were younger (age 59±18.3 vs 73.1±12.6 years old, p<0.001), had a lower left ventricular ejection fraction (LVEF) [25% (IR 18–35%) vs 38% (IR 25–45%), p<0.001], were supported by IABP for longer time [6 (IR 2–18) vs 2 (IR 1–4) days, p<0.001], required more use of inotropes/vasoconstrictors [80.0% (n=80) vs 33.8% (n=102), p<0.001], and needed more often escalation to VA-ECMO [23.0% (n=23) vs 1.3% (n=4), p<0.001]. Non-ACS patients showed higher in-hospital mortality than ACS patients [46.0% (n=46) vs 33.9% (n=103), p=0.042]. Non-ACS patients were more frequently bridged to heart transplantation [20.0% (n=20) vs 0.3% (n=1), p<0.001] or LVAD [4.0% (n=4) vs 0.6% (n=2), p=0.055] than ACS patients; mortality after transplantation/LVAD did not significantly differ between the two groups [12.5% (n=3/24) vs 66.7% (n=2/3), p>0.05]. The incidence of IABP-related overall and major complications (including ischemic stroke, major bleeding, and peripheral or visceral ischemia) was not different with respect to the non-ACS vs ACS aetiology [major complications: 8.0% (n=8) vs 5.0% (n=15), p>0.05].
Conclusions
In our experience, in the clinical setting of CS treated with IABP, non-ACS patients show a worse clinical profile and prognosis than ACS patients, and more often require escalation to more advanced mechanical support and/or heart transplantation, while the incidence of IABP-related complications appears similar independently of the aetiology.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Garofalo
- Policlinico IRCCS Sant'Orsola-Malpighi - Alma Mater Studiorum Università di Bologna, Dipartimento Cardio-Toraco-Vascolare - Medicina Specialistica, Diagnostica e Sperimentale , Bologna , Italy
| | - A Corsini
- Policlinico IRCCS Sant'Orsola-Malpighi, Dipartimento Cardio-Toraco-Vascolare , Bologna , Italy
| | - L Potena
- Policlinico IRCCS Sant'Orsola-Malpighi, Dipartimento Cardio-Toraco-Vascolare , Bologna , Italy
| | - M Schinzari
- Policlinico IRCCS Sant'Orsola-Malpighi - Alma Mater Studiorum Università di Bologna, Dipartimento Cardio-Toraco-Vascolare - Medicina Specialistica, Diagnostica e Sperimentale , Bologna , Italy
| | - E Nardi
- Policlinico IRCCS Sant'Orsola-Malpighi - Alma Mater Studiorum Università di Bologna, Dipartimento Cardio-Toraco-Vascolare - Medicina Specialistica, Diagnostica e Sperimentale , Bologna , Italy
| | - F Barberini
- Policlinico IRCCS Sant'Orsola-Malpighi, Dipartimento Cardio-Toraco-Vascolare , Bologna , Italy
| | - C Gargiulo
- Policlinico IRCCS Sant'Orsola-Malpighi - Alma Mater Studiorum Università di Bologna, Dipartimento Cardio-Toraco-Vascolare - Medicina Specialistica, Diagnostica e Sperimentale , Bologna , Italy
| | - M Malaguti
- Alma Mater Studiorum Università di Bologna, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale , Bologna , Italy
| | - M Sabatino
- Policlinico IRCCS Sant'Orsola-Malpighi, Dipartimento Cardio-Toraco-Vascolare , Bologna , Italy
| | - F Semprini
- Policlinico IRCCS Sant'Orsola-Malpighi, Dipartimento Cardio-Toraco-Vascolare , Bologna , Italy
| | - N Galie
- Policlinico IRCCS Sant'Orsola-Malpighi - Alma Mater Studiorum Università di Bologna, Dipartimento Cardio-Toraco-Vascolare - Medicina Specialistica, Diagnostica e Sperimentale , Bologna , Italy
| | - S Nanni
- Policlinico IRCCS Sant'Orsola-Malpighi, Dipartimento Cardio-Toraco-Vascolare , Bologna , Italy
| |
Collapse
|
2
|
Angeli F, Paolisso P, Magnani I, Fabrizio M, Rinaldi A, Armillotta M, Stefanizzi A, Amicone S, Tattilo FP, Suma N, Bodega F, Canton L, Galie N, Foa A, Pizzi C. Development and validation of a diagnostic echocardiographic mass (DEM) score in the complex approach to cardiac masses. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Cardiac masses (CM) are an extremely heterogeneous clinical entity, including benign and malignant neoformations. 2D Echocardiography is nowadays the first-line approach to define nature and management of CM.
Purpose
The purpose of our study was to identify the echocardiographic predictors of malignancy and create a multiparametric score to further increase the diagnostic yield and accurately suggest the nature of CM.
Material and methods
249 consecutive patients undergoing a complete echocardiographic assessment for suspected cardiac mass were enrolled from January 2004 to December 2020. A definitive diagnosis was achieved by histological examination or, in case of cardiac thrombi, with radiological evidence of thrombus resolution after an appropriate anticoagulant treatment. Logistic regression was performed to evaluate the ability of echocardiography to discriminate benign versus malignant masses.
Results
A scoring system was developed in a derivation cohort of 178 (70%) and validated in 71 (30%) patients. A weighted score [Diagnostic Echocardiographic Mass (DEM) Score] ranging from 0 to 9 was obtained from 6 variables: infiltration, polylobate mass, moderate-severe pericardial effusion, inhomogeneity, sessile and non-left localization. The AUC for the score was 0.965 (95% CI 0.938–0.993). In a logistic regression analysis using the DEM score as a predictor, the likelihood of malignancy increased more than 4 times for a 1-unit increase of the score (OR=4.468; 95% CI 2.733–7.304). The prognostic validity of the score was confirmed by its ability to predict survival during follow-up (median time of 31 months).
Conclusions
The application of a multiparametric echocardiographic score in the approach to CM accurately predicts mass malignancy thereby reducing the need for second-level investigations, and minimizing the diagnostic delay in such a complex clinical scenario.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- F Angeli
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - I Magnani
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - M Fabrizio
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - A Rinaldi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - M Armillotta
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - A Stefanizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - S Amicone
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - F P Tattilo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - N Suma
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - F Bodega
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - L Canton
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - C Pizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| |
Collapse
|
3
|
Martignani C, Ziacchi M, Statuto G, Spadotto A, Angeletti A, Massaro G, Bartoli L, Orlandi M, Diemberger I, Ginex S, Provasi F, Grassini D, Galie N, Biffi M. Rapid mode in novel generation visually guided laser balloon system: feasibility, safety, and impact on procedural outcomes. Europace 2022. [DOI: 10.1093/europace/euac053.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Laser balloon (LB) systems are increasingly used for pulmonary vein isolation (PVI) in catheter ablation of atrial fibrillation (AF). The novel generation of the visually guided LB system includes a rapid mode (RM) feature, which potentially allows a continuous circumferential lesion for PVI. Nevertheless, data on its practicability and on its impact on procedural outcomes are lacking.
Purpose
To analyse the applicability of RM and its effect on procedural and fluoroscopic time in a cohort of patients who underwent catheter ablation of AF using a LB system.
Methods
Between September 2020 and December 2021, we prospectively included all consecutive patients who underwent PVI with LB at our centre. All the procedures were performed by the same two operators. For each pulmonary vein (PV), we firstly attempted to obtain a complete circumferential lesion at 13 W using the RM. If its application was not possible or incomplete, we performed additional single lesions at 5.5, 8.5 or 13 W to achieve complete visual PVI. Finally, we calculated the percentage of singular and total circumferential lesions made with RM for every procedure and evaluated its influence on procedural outcomes.
Results
75 patients were enrolled. We identified and successfully isolated 289 PVs, with mean procedural and fluoroscopic time of 171±51 and 38±15 min, respectively. Use of RM for more than 70% of the circumferential lesion was possible in 185 veins (64%), while we obtained complete isolation using only RM in 90 veins (31%). Reasons for interruption of RM were unfavourable anatomy, imperfect visualization of the ostium of the PV and presence of blood between the balloon and the anatomic substrate. For each vein, we observed a significantly shorter ablation (13±8 vs 23±12 min, p<0.001) and fluoroscopic time (3±3 vs 5±4 min, p<0.01) if >70% of the circumferential lesion was made through RM. Further, total procedural (157 ±52 vs 192±42 min, p<0.01), ablation (53±17 vs 88±27, p >0.001) and fluoroscopic time (30±15 vs 36.9±14 min, p 0.025) were significantly shorter if more than 70% of total circumferential lesion was achieved through rapid mode. There were five pinhole balloon ruptures during application of RM. No major complication occurred.
Conclusions
RM is a novel feature in the latest generation of LB system. In our cohort, it showed good applicability and safety, while significantly reducing procedural times. Further studies are needed to understand its possible impact on clinical outcomes.
Collapse
Affiliation(s)
- C Martignani
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Orlandi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | | | | | - N Galie
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
4
|
Spadotto A, Toniolo S, Bartoli L, Statuto G, Angeletti A, Massaro G, Martignani C, Ziacchi M, Diemberger I, Galie N, Biffi M. Implantable cardioverter defibrillator in arrhythmogenic cardiomyopathy: which role for antitachycardia pacing? Europace 2022. [DOI: 10.1093/europace/euac053.387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Arrhythmogenic Cardiomyopathy (ACM) is an inherited cardiomyopathy characterized by ventricular arrhythmias and sudden cardiac death. Implantable cardioverter defibrillator (ICD) remains the only proven therapy to reduce mortality in ACM.
Purpose
The objective of this study was to identify characteristics of ventricular arrhythmias and treatment in patients with ACM.
Method
Retrospective analysis of the data of consecutives patients with confirmed diagnosis of ACM based on the proposed Padua Criteria, who underwent implantation of transvenous ICD from January 1992 and October 2021. The clinical data and information about appropriate and inappropriate ICD therapies were obtained from medical records with the review of the available intra-cardiac electrograms (EGMs).
Results
We enrolled 52 patients (69% males, mean age at implant 48.9 ±14.8 years), 27 (52%) were implanted for primary prevention, 25 (48%) for secondary prevention. After a median follow-up of 7.52 years [IQR: 4.37 - 12.0], 32 patients (61.5%) had 914 sustained episodes of ventricular arrhythmias (VA). 25 patients (48%) had 309 episodes of life-threatening arrhythmias (LT-VA), defined as sustained ventricular tachycardia ≥200 beats/min. In 29/32 patients (91%) ATP treated at least one episode of VA and in 14/25 (56%) at least one episode of LT-VA. Ventricular tachycardia (VT) detection was programmed at least 20 seconds, while VF detection was at least 7 seconds. Among patients with appropriate ICD activation, the first treated episode was a LT-VA in 50% of cases. Out of 914 VA episodes, 735 (80.4%) were treated with ATP and 179 (19.6%) with shocks. Considering LT-VA (cycle length 248 ± 25 ms), 201/309 (65%) and 108/309 (35%) episodes were treated with ATP and shocks, respectively. In 13 patients (25%) there was an inappropriate ICD activation, mostly caused by atrial fibrillation, while in 8 patients (15%) there was a complication needing reintervention (in 3 cases there was a loss of ventricular sensing dictating lead revision).
Conclusions
ACM patients are at risk of VA and LT-VA. The majority of VA at follow-up are monomorphic at rate <200 beats/minute, however the first treated VA episode is a LT-VA in half of cases. ATP is highly successful in terminating VT and even LT-VA, which questions the use of non-transvenous ICD in this young patient population. Nevertheless, transvenous ICDs are burdened by a relevant rate of lead complications which should be weighed in the choice of the ICD type.
Collapse
Affiliation(s)
- A Spadotto
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - S Toniolo
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - L Bartoli
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - G Statuto
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - A Angeletti
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - G Massaro
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | | | - M Ziacchi
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | | | - N Galie
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - M Biffi
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| |
Collapse
|
5
|
Martignani C, Ziacchi M, Statuto G, Spadotto A, Angeletti A, Massaro G, Bartoli L, Cascioli G, Ginex S, Grassini D, Diemberger I, Galie N, Biffi M. Learning curve for laser balloon ablation in the treatment of atrial fibrillation: a single center experience. Europace 2022. [DOI: 10.1093/europace/euac053.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Visually guided laser balloon ablation (LBA) is a promising method for pulmonary vein (PV) isolation in the treatment of atrial fibrillation (AF). To reduce procedural times, the rapid mode feature (RM), which offers an automated continuous 360° lesion for pulmonary vein isolation, was implemented in the latest version of the laser balloon system.
Purpose
We evaluated the learning curve for LBA in the treatment of AF
Method
We enrolled the first 74 patients with paroxysmal or persistent AF treated with LBA in our centre between September 2020 and December 2021. Exclusion criteria were any contraindication for the procedure. 3 different time intervals were considered (time 1 T1, time 2 T2 and time 3 T3), which included the first 25 patients, the next 25 patients and the last 24 patients, respectively. We compared fluoroscopy and procedural time and the number of pulmonary veins isolated by RM >90% (>324°) among the three group were compared.
Results
There was no difference between the three intervals in terms of age (61.2 ±9.00 vs 63.9 ±11.4 vs 58.4 ±12.9; p=n.s.), sex (68% vs 64% vs 81%; p=n.s.) and clinical characteristics. The procedural time (see picture 1) was significantly reduced from T1 to T2 (199 ±51.8 in T1 vs 159 ±38.6 in T2; p< 0.01), while there was no variation between T2 and T3 (159 ±38.6 in T2 vs 153 ±51.9 in T3; p=n.s.). We detected a reduction in fluoroscopy time between T1 and T2 (38.8 ±15.2 in T1 vs 28.8 ±10.5 in T2; p<0.01) but not further reduction was observed between T2 and T3 (28.8 ±10.5 in T2 vs 30.5 ±16.7 in T3; p =n.s.). Considering the use of (RM) feature, there was a progressive increase in the number of PVs isolated by RM >90% over time (1.0 ±0.7 PVs in T1 vs 2.0 ±1.2 PVs in T2 vs 3.3 ±0.9 in T3: p <0.01). Five pinhole balloon ruptures were observed, three in the T1 group, two in the T3 group. Temporary phrenic nerve dysfunction occurred in 1 patient in the T3 interval. No other complications were reported.
Conclusions
PV isolation by visually guided LBA is a safe procedure even during the learning curve. The system is user friendly and procedural time and fluoroscopy time reduced after a limited number of procedures.
Collapse
Affiliation(s)
- C Martignani
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Cascioli
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | | | - I Diemberger
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - N Galie
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
6
|
Magnani I, Paolisso P, Chiti C, Angeli F, Bergamaschi L, Foa A, Rinaldi A, Fabrizio M, Stefanizzi A, Armillotta M, Sansonetti A, Galie N, Pizzi C. Usefulness of CHA2DS2-VASc scoring system for predicting risk of embolism in patients with cardiac tumours: a single-centre study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The CHA2DS2-VASc score is the most used in predicting thromboembolic risk in patients with atrial fibrillation (AF). However, a higher CHA2DS2-VASc score predicts cardiovascular events even in patients without AF. Up to date, there is limited evidence about the association between CHA2DS2-VASc score and the embolic risk in patient with cardiac tumours (CT).
Purpose
To evaluate the role of the CHA2DS2-VASc score in predicting embolism and to identify other markers of embolization in patients with CT.
Methods
We included all patients with a CT who had a complete echocardiographic evaluation and a histologic diagnosis. We excluded patients with cardiac thrombi because of their higher embolic risk.
Results
Our sample consisted of 221 patients (mean age 60.9±15.6, 7% female). 132 (59.7%) patients had benign CT, usually left-sided (84.8%). In the malignant tumours, 28 (31.5%) were primary and 61 (68.5%) were metastasis. Compared to benign tumours, malignant ones were predominantly right-sided (47.2%) or with pericardial (20.2%) or great-vessels involvement (16.9%). A total of 59 patients (26.6%) experienced an embolic event, of which 33 patients had peripheral embolism, while 28 had pulmonary embolism (PE), 2 patients had both. Patients with embolism were older (p=0.013), had a higher prevalence of diabetes or previous stroke (p=0.019 and p<0.001), had left-sided and not-infiltrating CT (p=0.001 and p=0.04). We did not find any differences in AF prevalence, atrium volumes or other CT characteristics. Moreover, patients who developed an embolic event had a higher CHA2DS2-VASc score than those without embolism (p<0.001). In particular, a CHA2DS2-VASc score >3 had an AUC=0.835 in predicting a peripheral embolic event in the overall population (p<0.001). At multivariate analysis, only CHA2DS2-VASc and left-side localization were significantly associated with embolization (p<0.001 and p=0.009).
Also in patients with right-sided CT, CHA2DS2-VASc score (p=0.017), together with some tumours characteristics (mobility, pericardial effusion and absence of myocardial infiltration (p<0.04 for all) was associated with PE.
Embolization did not impact survival when considering the overall population. Otherwise, when focusing on patients with malignant CT, those who had an embolic event had a worse prognosis (p=0.02), as well as those with PE (p=0.037).
Conclusions
CHA2DS2-VASc and left-side localization are the best markers of embolism. In particular, CHA2DS2-VASc seems to predict embolization in CT, regardless of histology or localization. Many patients with CT and embolism may not be offered surgical treatment given their assumed high-risk profile. By contrast, our analysis showed that survival is not related to the embolic event per se, but by histology. In patients with CT and high CHA2DS2-VASc score, further studies are needed to evaluate the best therapeutic strategy to minimize the embolic risk.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- I Magnani
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Chiti
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - F Angeli
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Bergamaschi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Rinaldi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Fabrizio
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Stefanizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Armillotta
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Sansonetti
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Pizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
7
|
Rotunno M, Dardi F, Palazzini M, Guarino D, Zuffa E, Magnani I, De Lorenzis A, Ballerini A, Manes A, Galie N. Echocardiographic predictors of low risk haemodynamic parameters in patients with pulmonary arterial hypertension. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
A periodic and multiparametric assessment of the risk profile of patients with pulmonary arterial hypertension (PAH) is essential for a low-risk oriented treatment strategy. Haemodynamic parameters anyway cannot be collected at each scheduled outpatients clinic follow-up visit.
Purpose
To evaluate echocardiographic predictors of haemodynamic low-risk parameters in patients with PAH.
Methods
Patients with PAH referred to our centre were included up to 31 December 2019. All patients underwent baseline demographic, clinical, WHO functional class, 6-minute walk test, brain natriuretic peptide (BNP), right cardiac catheterization and echocardiographic evaluation. Through a multivariate logistic regression analysis we evaluate the echocardiographic predictors of low risk for: 1) BNP/right atrial pressure (RAP): NT-proBNP <300 ng/l/BNP <50 ng/l AND RAP <8 mmHg; 2) cardiac index (CI)/mixed venous oxygen saturation (SvO2): CI ≥2.5 l/min/m2 AND SvO2 >65%. Echocardiographic parameters cut-offs were chosen on the basis of the ROC curves or Literature data.
Results
1020 patients were included. The two analysis were performed independently.
1. Independent echocardiographic predictors of low-risk BNP/RAP were: indexed right atrial area, mitral E/A ratio, dimension and inspiratory collapse of inferior vena cava and indexed left ventricular diastolic volume. We elaborated a score utilizing these parameter cut-offs: an indexed right atrial area of 10.4–15 cm2/m2, a mitral E/A ratio of 0.8, dimension and inspiratory collapse of inferior vena cava indicative of 0–5 vs 5–10 vs 10–20 mmHg and an indexed left ventricular diastolic volume of 32 ml/m2. The score has AUC: 0.62, specificity: 92%, sensitivity: 33%, negative predictive value: 70%, positive predictive value: 69%.
2. Independent echocardiographic predictors of low-risk CI/SvO2 were: S wave at TDI, Tei index, tricuspid annular plane systolic excursion (TAPSE), indexed left ventricular diastolic volume and the severity of the tricuspid regurgitation. We elaborated a score utilizing these parameter cut-offs: an S wave at TDI of 9.5 cm/s, a Tei index of 0.4, a TAPSE of 1.7 cm, an indexed left ventricular diastolic volume of 32 ml/m2 and a mild vs more than mild tricuspid regurgitation. The score has AUC: 0.70, specificity: 89%, sensitivity: 50%, negative predictive value: 71%, positive predictive value: 77%.
Conclusion
Echocardiographic parameters can be used to rule out the presence of low-risk BNP/RAP values (indexed right atrial area, mitral E/A ratio, dimension and inspiratory collapse of inferior vena cava and indexed left ventricular diastolic volume) and low-risk CI/SvO2 (S wave at TDI, Tei index, TAPSE, indexed left ventricular diastolic volume and severity of tricuspid regurgitation).
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Rotunno
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Dardi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Palazzini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - D Guarino
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - E Zuffa
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - I Magnani
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A De Lorenzis
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Ballerini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Manes
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Galie
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| |
Collapse
|
8
|
Angeli F, Bartoli L, Fabrizio M, Bergamaschi L, Magnani I, Paolisso P, Armillotta M, Sansonetti A, Chiti C, Stefanizzi A, Toniolo S, Foa A, Rinaldi A, Galie N, Pizzi C. Cancer incidence during follow-up in patients with new-onset atrial fibrillation treated with DOACs and its impact on bleeding risk. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Cancer is increasingly recognized as strictly related to atrial fibrillation (AF). In patients with AF, the relationship between cancer and cardioembolic or bleeding risk during oral anticoagulant therapy is unknown.
Purpose
To assess the bleeding and ischaemic burden of a baseline or newly diagnosed cancer in patients treated with direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (NVAF).
Methods
All consecutive patients treated with DOACs were enrolled among those with new-onset atrial fibrillation and indication for oral anticoagulant between January 2017 and March 2019. During follow-up, bleeding events, newly diagnosed primitive or metastatic malignancy and major cardiovascular events (MACE) were evaluated. At baseline, CHA2DS2-VASc, HAS-BLED, ATRIA, and ORBIT scores were used to assess the hemorrhagic and ischaemic risk. Major bleedings (MB) were defined according to the ISTH definition. Anemia was defined as haemoglobin levels below 11 g/dL in women and 12 mg/dL in men.
Results
1258 patients constituted the study population and followed for a mean time of 21.6±9.5 months. Overall, 66 patients (5.2%) were affected by malignant neoplasia at baseline, whereas 59 (4.7%) were diagnosed with a malignancy during follow-up. Among baseline characteristics, anemia was associated with cancer at enrolment (43.9% vs 22.5%, p<0.001) but not at follow up (29.3% vs 23.4%, p=0.341). MACEs were not associated with cancer at baseline (5.3% vs 5.2%, p=1.0) and at follow up (5% vs 4.9%, p=1.0). No association was observed between major ischaemic events and cancer at enrolment or follow up (5.3% vs 4.4%, p=0.83 and 4.4% vs 5%, p=0.82). Despite no statistically significant differences in haemorrhagic risk at baseline, the overall bleeding events and MB were associated with newly diagnosed cancer (9.2% vs 3.9%, p=0.001 and 13.8% vs 4.5%, p=0.001, respectively) but not at baseline (5.2% vs 5.5%, p=0.82 and 9.2% vs 5.2%, p=0.162). At multivariate analysis adjusted for age, hypertension and renal function, anemia and a newly diagnosed cancer during follow up remained independent predictors of MB (respectively, HR 1.27, 95% CI 1.52–1.06, p=0.009 and HR 3.53, 95% CI 7.71–1.62, p=0.001).
Conclusion
Bleeding risk assessment is an ongoing challenge in patients with NVAF on DOACs. During follow-up, newly diagnosed primitive or metastatic cancer is a strong predictor of bleeding regardless of baseline haemorrhagic risk assessment. In contrast, such association is not observed with malignancy at baseline. A proper diagnosis and treatment could therefore decrease cancer-related bleeding risk. On the contrary, our study shows that cancer is not an ischaemic risk modifier, either diagnosed at baseline or follow-up.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- F Angeli
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Bartoli
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Fabrizio
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Bergamaschi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - I Magnani
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Armillotta
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Sansonetti
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Chiti
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Stefanizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - S Toniolo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Rinaldi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Pizzi
- University of Bologna, Bologna, Italy
| |
Collapse
|
9
|
Magnani I, Dardi F, Palazzini M, Zuffa E, Guarino D, Daddi N, Dolci G, Antonacci F, Solli P, Paganelli GM, De Lorenzis A, Rotunno M, Ballerini A, Manes A, Galie N. Survival of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension listed for lung transplantation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Lung transplantation (LT) still remains a treatment option for patients with pulmonary arterial hypertension (PAH) and not operable chronic thromboembolic pulmonary hypertension patients (CTEPH).
Purpose
The study is intended to compare the survival of transplant recipients (TR) and the survival of not-transplanted (NT) patients since listing.
Methods
We included all patients with PAH and not-operable CTEPH listed for LT. The survival of NT, TR and of all listed patients was evaluated starting from the date of listing (patients were censored as alive at the time of LT). The survival of TR was also evaluated starting from the date of the LT.
Results
125 patients were included (112, 90% had PAH). Fifty-eight (46%) patients were transplanted, after a mean waiting time of 1.5±1.3 years. Forty-one patients (33%) died while on the list and 25 (20%) patients were alive on the list on December 2019. The survival of NT patients at 1, 3 and 5 years after listing was 74%, 42%, 33%, respectively. The survival of TR patients at 1, 3 and 5 years after listing was 90%, 70%, 63%, respectively. The survival of all patients since listing (intention to treat analysis) at 1, 3 and 5 years was 85%, 59%, 48% respectively. The survival of TR at 1, 3 and 5 years since transplantation was 63%, 61%, 59%, respectively.
Conclusions
Despite biases in the comparison of non-randomized groups, the data confirm a better long-term survival since listing of TR as compared with NT PAH or not-operable CTEPH patients.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- I Magnani
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Dardi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Palazzini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - E Zuffa
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - D Guarino
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Daddi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - G Dolci
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Thoracic surgery, Bologna, Italy
| | - F Antonacci
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Thoracic surgery, Bologna, Italy
| | - P Solli
- Maggiore Hospital, Bellaria Hospital, Presidio Ospedaliero Bellaria-Maggiore, Thoracic Surgery, Bologna, Italy, Bologna, Italy
| | - G M Paganelli
- Policlinico S. Orsola-Malpighi, Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Pulmonology, Bologna, Italy
| | - A De Lorenzis
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Rotunno
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Ballerini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Manes
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Galie
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| |
Collapse
|
10
|
Martignani C, Ziacchi M, Statuto G, Bartoli L, Spadotto A, Angeletti A, Massaro G, Diemberger I, Sorrentino S, Capobianco C, Grassini D, Ginex S, Giacopelli D, Galie N, Biffi M. Real use of a novel automatic motorized laser balloon for the ablation of atrial fibrillation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Electric isolation of the pulmonary veins (PVs) can successfully treat patients with atrial fibrillation (AF). Isolation of pulmonary veins can be achieved by several methods: radiofrequency, cryoballoon or laser balloon ablation (LBA). The main procedural challenge with either method is to achieve a continuous circumferential lesion at the left atrium-PVs junction, with the persistence of functional gaps.
Purpose
A novel endoscopic ablation system equipped with a precise motor control system (MCS) has been evaluated. The balloon is used with an endoscope to directly visualize and ablate tissue at the left atrial-PVs junction with laser energy. This system enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician. The MCS is intended to reduce procedure time and to ensure continuity of ablation lesions. The feasibility of the motorized ablation in terms of extent of applicability along each PV-left atrium junction and time of use of the manual point-by-point mode has been investigated.
Methods
27 consecutive patients (male 70.3%, age 61.2±8.7 years) with paroxysmal or persistent AF who underwent LBA were enrolled in our institution. Exclusion criteria were any contraindication for the procedure including the presence of intracavitary thrombosis and contraindications to general anesthesia or deep sedation. After transseptal puncture, the balloon-based endoscopic ablation system was advanced to each PV ostium, and laser energy were projected onto the target.
Results
A total of 110 PVs were treated with LBA; in 9 patients there was a redundant right intermediate pulmonary vein; in 4 patients there was a right common ostium and in 2 a left common ostium. MCS was used for 82 PVs (74.5%): in particular, MCS was used continuously between 180° and 325° degrees (50 to 90% of PV circumference) for 35 PVs (31.8%) and between 326° and 359° degrees (91 to 99% of PV circumference) for 25 veins (22.7%). In 13 PVs (12%) MCS was used for the entire circumference. During 8508 (19.6%) seconds out of a total of 43.368 seconds, laser energy delivery occurred in the rapid mode by MCS.
No clinical complications, either local or systemic (stroke or TIA, pericardial effusion, pericardial tamponade, pulmonary vein stenosis, esophageal injury, temporary or permanent phrenic nerve palsy), were observed neither during the use of MSC nor during the use of manual point-by-point mode. Of note, a pinhole rupture of the balloon occurred in 3 cases of our series, during the use of MCS, without harm to the patient and requiring only replacement of the LBA.
Conclusions
In our case series, laser balloon ablation with the help of motor control system appears safe and feasible in most cases for large portions of pulmonary vein circumference, providing considerable time sparing (74.5% of total ablation extent in 19.6% of total ablation time).
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- C Martignani
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Sorrentino
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - C Capobianco
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | | | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | | | - N Galie
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
11
|
Saturi G, Santona L, Sguazzotti MS, Caponetti AG, Massa P, Ponziani A, Gagliardi C, Giovannetti AG, Lovato L, Attina D, Bonfiglioli R, Saia F, Galie N, Biagini E, Longhi S. Different aortic valve calcium scores by computed tomography scan in patients with severe aortic stenosis and concomitant cardiac amyloidosis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The coexistence of cardiac amyloidosis (CA) and degenerative aortic stenosis (AS) is increasing but the diagnosis is challenging because these two conditions share a common echocardiographic phenotype (1). Different predictors have been proposed in the last few years, including clinical, ECG-graphic and echocardiographic features (2–3).
Purpose
To identify a new marker of concomitant CA in patients with severe AS analyzing computed tomography scan (CT).
Methods
55 patients with severe AS and suspicion of concomitant CA were retrospectively enrolled. Patients with a bicuspid aortic valve, previous aortic valve replacement, or an incomplete diagnostic workup for CA were excluded. 33 patients underwent CT-scan and were included in the final analysis.
Results
None of the patients presented laboratory suspicion for AL amyloidosis; 12 patients (AS-CA) had positive 99m Tc-DPD bone scintigraphy (two with visual score 1, eight score 2 and two score 3), 21 patients (AS-alone) had negative bone scintigraphy. AS-CA patients had a median age of 85,5 years (versus 81,5) with only one female patient (versus 8 in the AS-alone group). AVA indexed were comparable between AS-CA and AS-alone groups (0,4 versus 0, 3 mm2/m2, p: 0.25). Stroke volume evaluated by pulsed Doppler, maximum and mean gradient were significatively lower in AS-CA group (respectively 30 versus 41 ml/m2, p: 0.017, 62 versus 74 mmHg, 0.038 and 33 versus 46 mmHg, p:0.022) with a higher percentage of low flow-low gradient aortic stenosis in AS-CA group (7 patients, 58% vs 3 patients in AS-alone 14%, p: 0.027), in line with the literature. ECG at first presentation in AS-CA group showed atrial fibrillation in 8 patients (67%), versus 2 patients in the AS-alone group (10%), and lower QRS voltages (peripheral QRS score 40 mV vs 51 mV, p-value:0.017; total QRS score 113 mV versus 155 mV, p-value: 0.005). The echocardiogram showed a more thickened IVS and PW in AS-CA patients (17 versus 15 mm, p: 0.05 and 15 versus 14 mm, p: 0.013), an augmented left ventricular mass (441 versus 356 g, p: 0.036) with a decreases longitudinal systolic function (septal S wave at TDI 4.4 versus 5.2 cm/s, p: 0.026, lateral S wave 4.1 versus 5.6 cm/s, p: 0.024) and a reduction in myocardial contraction fraction (12 versus 14%, p: 0.036).
CT- aortic valve calcium was quantified by an experienced operator. A statistically significant difference between AS-CA and AS-alone groups was observed in calcium score (3345 versus 4785 Hounsfield units, p: 0.037) calcium volume (2411 versus 3626 mm2, p: 0.03) and calcium mass (687 versus 1147 g, p: 0.023)
Conclusions
This study is the first to our knowledge to use relative aortic valve calcium score evaluation from CT imaging to characterize patients with severe AS with or without concomitant CA in addition to the classical clinical, ECG graphic, echocardiographic parameters. CT-aortic valve calcium burner was significatively lower in patients with concomitant CA.
Funding Acknowledgement
Type of funding sources: None. CT scan and bone scintigraphy
Collapse
Affiliation(s)
- G Saturi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - L Santona
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - M S Sguazzotti
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - A G Caponetti
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - P Massa
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - A Ponziani
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - C Gagliardi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - A G Giovannetti
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - L Lovato
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - D Attina
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - R Bonfiglioli
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - F Saia
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - N Galie
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - E Biagini
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - S Longhi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| |
Collapse
|
12
|
Sguazzotti M, Caponetti AG, Saturi G, Ponziani A, Massa P, Dal Passo B, Accietto A, Longhi S, Bonfiglioli R, Mattana F, Guaraldi P, Cortelli P, Galie N, Biagini E, Gagliardi C. Analysis of characteristics and prognostic impact of phenotypes in hereditary ATTR. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Hereditary transthyretin-related amyloidosis (h-ATTR) is a systemic infiltrative disease caused by a single amino acid mutation on the transthyretin (TTR) gene, which destabilizes the protein and can determine its deposition on multiple organs, including heart and peripheral nervous system.
Purpose
We aimed to characterize and compare clinical, instrumental, and prognostic features of patients affected by h-ATTR by dividing the population into the disease's main phenotypes (unaffected carriers, cardiac, neurological or mixed phenotype).
Methods
Two hundred and eighty-five subjects of a single-centre cohort with a recognized pathogenic mutation on TTR gene were retrospectively included in the analysis. Phenotypes of disease were defined at baseline. Neurological phenotype (NP) was defined according to sensorimotor and/or autonomic dysfunction, while cardiac phenotype (CP) was defined in the presence of unexplained maximum wall thickness >12 mm and other typical echocardiographic findings. Unaffected carriers (UC) and mixed phenotypes (MP) presented none or both of the above-mentioned features, respectively.
Results
Two hundred and ten patients showed clinical signs of the disease, 37 (13%) with CP, 65 (23%) with NP and 108 (38%) with MP, while 75 subjects (26%) were UC. Ile68Leu was the most represented mutation (96 subjects, 34%), followed by Val30Met (21%) and Glu89Gln (13%). NP patients (mostly Val30Met) had mPND score >1 in 45% of patients, were younger at diagnosis (mean 47 years, p<0,001 vs CP/MP), and sex was equally distributed. In contrast, CP patients were older at diagnosis (mean 70 years, p<0,001 vs CP/MP), predominantly male (as well as in MP) with a higher incidence of tunnel carpal syndrome and a shorter time interval between onset of symptoms and diagnosis (mean 17 months, p<0,001 vs CP/MP). NYHA class, ECG findings, left ventricular wall thickness and ejection fraction did not significantly differ between CP and MP. After a mean follow-up of 59 months, 98 (34%) patients died. On a Kaplan-Meier survival analysis, mean survival times were 208, 123, 150 and 95 months for UC, CP, NP and MP, respectively, with a statistically significant difference in affected patients between NP and MP (p=0.012).
Conclusions
H-ATTR is a rare systemic disorder whose natural history, including age of onset, clinical characteristics and instrumental findings, is strongly influenced by primary phenotypes, ranging from the excellent prognosis of unaffected carriers to the inauspicious outcome of mixed phenotypes.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Sguazzotti
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - A G Caponetti
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - G Saturi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - A Ponziani
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - P Massa
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - B Dal Passo
- Alma Mater Studiorum, University of Bologna, Bologna, Italy
| | - A Accietto
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - S Longhi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - R Bonfiglioli
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - F Mattana
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | | | | | - N Galie
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - E Biagini
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - C Gagliardi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| |
Collapse
|
13
|
De Lorenzis A, Dardi F, Guarino D, Palazzini M, Magnani I, Zuffa E, Ballerini A, Rotunno M, Manes A, Galie N. Role of cardiac magnetic resonance in stratifying the prognosis of patients with pulmonary arterial hypertension. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Pulmonary arterial hypertension (PAH) is a rare disease characterized by a complex remodeling of heart structures. Cardiac magnetic resonance (CMR) is the gold standard for a non-invasive evaluation of right ventricle (RV) volumes and mass.
Purpose
To define the relationship between clinical, functional, biochemical, haemodynamic and CMR parameters and survival in patients with PAH.
Methods
Consecutive patients with PAH referred to our centre underwent clinical, functional, brain natriuretic peptide (BNP) plasma levels, haemodynamic and CMR evaluation. All patients were treated according to current guidelines. Univariate Cox analysis for survival was performed. Parameters with a p-value <0.1 at the univariate analysis were included in the multivariate analysis.
Results
One hundred forty-seven patients with PAH (mean age 49±17 years, 69% female) were included in the study. Etiology of PAH was: idiopathic/heritable (49%), associated with connective tissue disease (19%), congenital heart disease (12%), portal hypertension/HIV infection (12%) and pulmonary veno-occlusive disease (8%). Thirty-six patients died during follow-up. Parameters significantly associated with mortality at the univariate analysis were age [Hazard Ratio (95% Confidence Interval): 1.043 (1.020–1.067); p<0.001], six-minute walk test (6MWT) [HR: 0.995 (0.993–0.998); p<0.001], WHO-functional class [HR: 2.489 (1.025–6.041); p=0.044], idiopathic-heritable-congenital heart disease aetiology [HR: 0.182 (0.085–0.389); p<0.001], connective tissue disease aetiology [HR: 2.274 (1.099–4.704); p=0.027], pulmonary veno-occlusive disease aetiology [HR: 5.864 (2.328–14.773); p<0.001], right atrial pressure [HR: 1.098 (1.032–1.169); p=0.003], pulmonary artery oxygen saturation [HR: 0.947 (0.921–0.975); p<0.001], BNP levels [HR: 2.214 (1.213–4.039); p=0.010], RV wall thickness [HR: 0.633 (0.399–1.006); p=0.053], RV end diastolic volume [HR: 1.012 (1.003–1.021); p=0.007], RV end systolic volume [HR: 1.014 (1.003–1.024); p=0.011]. Parameters independently associated with mortality at the multivariate analysis were age [HR: 1.035 (1.006–1.064); p=0.018], idiopathic-heritable-congenital heart disease aetiology [HR: 0.355 (0.146–0.860); p=0.022], pulmonary veno-occlusive disease aetiology [HR: 3.129 (1.071–9.143); p=0.037], pulmonary artery oxygen saturation [HR: 0.953 (0.919–0.989); p=0.011], RV wall thickness [HR: 0.527 (0.300–0.927); p=0.026], RV end systolic volume [HR: 1.016 (1.003–1.029); p=0.014].
Conclusion
RV wall thickness and RV end-systolic volume are associated with prognosis in patients with PAH independently from clinical and haemodynamic characteristics. These parameters may be used in the overall risk stratification of PAH patients.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A De Lorenzis
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Dardi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - D Guarino
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Palazzini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - I Magnani
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - E Zuffa
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Ballerini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Rotunno
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Manes
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Galie
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| |
Collapse
|
14
|
Coghlan GJ, Gaine S, Channick RN, Chin KM, Du Roure C, Gibbs JSR, Hoeper MM, Lang IM, Mathai SC, McLaughlin VV, Mitchell L, Simonneau G, Sitbon O, Tapson V, Galie N. Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
In PAH clinical practice, drugs targeting the prostacyclin pathway, including the oral prostacyclin receptor agonist selexipag, are often initiated years after diagnosis. The GRIPHON (NCT01106014) and TRITON (NCT02558231) randomised controlled trials examined the impact of selexipag on disease progression, primary and secondary endpoints, respectively. In GRIPHON, selexipag significantly reduced the risk of disease progression (composite primary endpoint) in a PAH population (N=1156) with a mean time from diagnosis of 2.4 years, as part of an oral triple, double or monotherapy regimen versus placebo. In TRITON, a potential signal for reduced risk of disease progression was observed with initial triple oral therapy (selexipag, macitentan, tadalafil) versus initial double oral therapy (placebo, macitentan, tadalafil) in a population of 247 newly diagnosed, treatment naïve patients.
Purpose
To investigate the impact of initiating selexipag within 6 months of diagnosis on disease progression in a large PAH population.
Methods
We selected patients from GRIPHON and TRITON diagnosed within 6 months of randomization and compared those on active therapy with selexipag (selexipag group) versus those on control therapy with placebo (control group). Disease progression endpoints were defined as in the GRIPHON and TRITON studies, respectively. Hazard ratios (HR) and 95% CI for time to first disease progression event up to end of double-blind treatment (selexipag/placebo) + 7 days were estimated using a Cox regression model which included treatment as a factor, and baseline prognostic factors and study as covariates.
Results
Overall, 649 patients met the criteria (diagnosis ≤6 months) for these analyses: 329 in the selexipag group (207 from GRIPHON and 122 from TRITON) and 320 in the control group (197 from GRIPHON and 123 from TRITON). Patient characteristics at baseline and treatment regimens were balanced between the treatment groups. With respect to treatment regimen, selexipag/placebo was given as part of triple therapy in 44%, double therapy in 32% and monotherapy in 24% of patients. The median (range) exposure to study treatment was 510 (4–1280) and 409 (3–1318) days in the selexipag and control groups, respectively. There were 67 (20%) and 116 (36%) patients who experienced a disease progression event in the selexipag and control groups, respectively. Selexipag reduced the risk of disease progression (first event) by 52% compared to control (HR 0.48 [95% CI 0.35, 0.66]) (Figure).
Conclusions
This post-hoc pooled analysis of GRIPHON and TRITON patients diagnosed within 6 months suggests that targeting the prostacylin pathway with selexipag within a short time after diagnosis may reduce the risk of disease progression in a broad PAH population.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson
Collapse
Affiliation(s)
| | - S Gaine
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - R N Channick
- University of California Los Angeles, Los Angeles, United States of America
| | - K M Chin
- University of Texas Southwestern Medical Center, Dallas, United States of America
| | - C Du Roure
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - J S R Gibbs
- National Heart & Lung Institute, Imperial College London, London, United Kingdom
| | - M M Hoeper
- Department of Respiratory Medicine, Hannover Medical School and German Center for Lung Research, Hannover, Germany
| | - I M Lang
- Division of Cardiology, Medical University of Vienna, Vienna, Austria
| | - S C Mathai
- Johns Hopkins University School of Medicine, Baltimore, United States of America
| | - V V McLaughlin
- University of Michigan, Ann Arbor, United States of America
| | - L Mitchell
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - G Simonneau
- Hôpital Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France
| | - O Sitbon
- Hôpital Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France
| | - V Tapson
- Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - N Galie
- DIMES, University of Bologna and IRCCS, S.Orsola University Hospital, Bologna, Italy
| |
Collapse
|
15
|
Orzalkiewicz M, Donati F, Santona L, Marcelli C, Chietera F, Bendandi F, Bruno AG, Ghetti G, Taglieri N, Palmerini T, Marrozzini C, Galie N, Saia F. Management strategies for acutely decompensated aortic stenosis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Uncertainty exists over the optimal treatment strategy for patients presenting with acutely decompensated severe aortic stenosis (AS). The available options include a bridging balloon aortic valvuloplasty (BAV) or a direct transcatheter aortic valve implantation (TAVI).
Purpose
Our study compares TAVI outcomes in patients treated with two different strategies in acutely decompensated severe AS: bridged TAVI vs direct TAVI.
Methods
In this observational study all patients admitted with decompensated severe AS who underwent balloon aortic balloon valvuloplasty (BAV) and/or TAVI on the index admission were included. Comparison was made between bridged TAVI group (defined as initial BAV followed by TAVI) and direct TAVI group (TAVI on the index admission without bridging BAV). For this analysis we excluded patients in cardiogenic shock. Baseline characteristics, echocardiographic and periprocedural data were recorded in hospital database. Major adverse cardiovascular events (MACE) were defined as death, major bleeding, rehospitalisation for heart failure, or stroke). The follow-up data was obtained by outpatient visits and/or telephone calls.
Results
178 patients with acutely decompensated AS were analysed: 58 bridged TAVI, 23 direct TAVI, 9 bridged SAVR and 88 destination BAV (defined as BAV non followed by a definite treatment). There was no statistically significant difference between bridged TAVI and direct TAVI group in mean age (83.6±6.6 vs 80.4±8.3 years), the prevalence major comorbidities (coronary, respiratory, neurological or peripheral vascular disease), renal function (eGFR 43.4±18.9 vs 45.2±20.9 ml/min/m2), the mean LV ejection fraction (53.4±13.8 vs 48.6±14.6%) or aortic valve gradient (39.4±13.0 vs 34.1±12.3mmHg), respectively. Direct TAVI patients had a higher mean surgical risk scores (STS 6.1±3.7 vs 9.1±7.0%, logES 18.8±11.5 vs 30.8±20.9%, p=0.01) and higher prevalence of significant aortic regurgitation (5% vs 43%, p=0.0001). The femoral TAVI access was used in 98% of bridged and 78% of direct TAVI patients (p=0.006). The estimated 1-year survival and 1-year MACE-free survival did not differ significantly between the bridged TAVI and direct TAVI groups (86.8% vs 78.3%, p=0.20 and 79.7% vs 64.2%, p=0.11, respectively).
Conclusions
A large proportion of patients admitted with acutely decompensated AS were not eligible for definite treatment. There is no difference in procedural success, 1-year all-cause mortality and 1-year major adverse cardiovascular events between the bridged TAVI or direct TAVI strategies in acute decompensated aortic stenosis allowing to personalize treatment strategy for individual patient.
Funding Acknowledgement
Type of funding sources: None. Table 1. Clinical and procedural data
Collapse
Affiliation(s)
| | - F Donati
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - L Santona
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - C Marcelli
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - F Chietera
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - F Bendandi
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - A G Bruno
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - G Ghetti
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - N Taglieri
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - T Palmerini
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - C Marrozzini
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - N Galie
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - F Saia
- St. Orsola-Malpighi University Hospital, Bologna, Italy
| |
Collapse
|
16
|
Martignani C, Ziacchi M, Statuto G, Bartoli L, Spadotto A, Angeletti A, Massaro G, Diemberger I, Sorrentino S, Capobianco C, Giacopelli D, Bassini M, Grassini D, Galie N, Biffi M. Third-generation laser balloon ablation: rapid mode applicability is associated with shorter time to pulmonary vein isolation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The rapid mode feature implemented in the latest version of the laser balloon system (LB3, HeartLight, X3, Cardiofocus) offers an automated continuous 360° lesion for pulmonary vein isolation (PVI). However, data on its clinical applicability and the potential reduction of procedural times are not yet available.
Purpose
To explore the use of the rapid mode and its association with PV total and fluoroscopy times in our initial experience with LB3.
Methods
This analysis included consecutive patients who underwent PVI procedure with LB3. We attempted to perform a complete circular ablation line using the rapid mode at 13 W, but if needed to achieve successful isolation, rapid mode was interrupted and manual mode (5.5–8.5 W) applications were used. The percentage of rapid mode use on the 360° lesion was measured for each PV. Total and fluoroscopy times to complete PVI were also collected.
Results
A total of 110 PVs were identified in 27 LB3 procedures and successfully isolated with a mean procedural time of 85±31 min. Sixty (55%) PVs were treated by using rapid mode for more than 50% (180°) lesion and 13 (12%) of them had a pure rapid mode ablation (without necessity of manual mode applications). Right inferior PV had the highest use of rapid mode (median value 70%). The main reasons for manual applications were poor PV occlusion, imperfect ostium visualization and presence of blood. PVs with >50% rapid mode use were treated in a significantly shorter time (21.2±13.7 vs 26.8±12.4, p=0.043). Fluoroscopy time did not differ significantly (4.7±4.2 vs 5.4±4.9, p=0.48). Three pinhole balloon ruptures were observed during rapid mode energy application in the second, third and twenty-fifth procedure. No other complications occurred.
Conclusions
Few PVs could be isolated using pure rapid mode; however, its applicability for more than 50% lesion was observed more frequently and significantly reduced the time to isolation.
Funding Acknowledgement
Type of funding sources: None. Time to isolation using Rapid Mode
Collapse
Affiliation(s)
- C Martignani
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - L Bartoli
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Sorrentino
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - C Capobianco
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | | | | | | | - N Galie
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant'Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
17
|
Martignani C, Ziacchi M, Statuto G, Spadotto A, Angeletti A, Massaro G, Diemberger I, Sorrentino S, Capobianco C, Grassini D, Giacopelli D, Ginex S, Galie N, Biffi M. Real use of a novel automatic motorized laser balloon for the ablation of atrial fibrillation. Europace 2021. [DOI: 10.1093/europace/euab116.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Electric isolation of the pulmonary veins (PVs) can successfully treat patients with atrial fibrillation (AF). Isolation of pulmonary veins can be achieved by several methods: radiofrequency, cryoballoon or laser balloon ablation (LBA). The main procedural challenge with either method is to achieve a continuous circumferential lesion at the left atrium-PVs junction, with the persistence of functional gaps.
Purpose
A novel endoscopic ablation system equipped with a precise motor control system (MCS) has been evaluated. The balloon is used with an endoscope to directly visualize and ablate tissue at the left atrial-PVs junction with laser energy. This system enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician. The MCS is intended to reduce procedure time and to ensure continuity of ablation lesions. The feasibility of the motorized ablation in terms of extent of applicability along each PV-left atrium junction and time of use of the manual point-by-point mode has been investigated.
Methods
sixteen consecutive patients (male 68.7%, age 60.9 ± 7.8 years) with paroxysmal or persistent AF who underwent LBA were enrolled in our institution. Exclusion criteria were any contraindication for the procedure including the presence of intracavitary thrombosis and contraindications to general anesthesia or deep sedation. After transseptal puncture, the balloon-based endoscopic ablation system was advanced to each PV ostium, and laser energy were projected onto the target.
Results
A total of 62 PVs were treated with LBA; in 3 patients there was a redundant right intermediate pulmonary vein; in 4 patients there was a right common ostium and in one a left common ostium. MCS was used for 41 PVs (66.1%): in particular, MCS was used continuously between 180° and 325° degrees (50 to 90% of PV circumference) for 22 PVs (35.5%) and between 326° and 359° degrees (91 to 99% of PV circumference) for 16 veins (25.8%). In 3 PVs (4.8%) MCS was used for the entire circumference. During 5.659 (23.6%) seconds out of a total of 23.986 seconds, laser energy delivery occurred in the rapid mode by MCS.
No clinical complications, either local or systemic (stroke or TIA, pericardial effusion, pericardial tamponade, pulmonary vein stenosis, esophageal injury, temporary or permanent phrenic nerve palsy), were observed neither during the use of MSC nor during the use of manual point-by-point mode. Of note, a pinhole rupture of the balloon occurred in the first 2 cases of our series, during the use of MCS, without harm to the patient and requiring only replacement of the LBA.
Conclusions
In our case series, laser balloon ablation with the help of motor control system appears safe and feasible in most cases for large portions of pulmonary vein circumference, providing considerable time sparing (66.1% of total ablation extent in 23.6% of total ablation time).
Collapse
Affiliation(s)
- C Martignani
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Ziacchi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Statuto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Spadotto
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - A Angeletti
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - G Massaro
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - I Diemberger
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - S Sorrentino
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - C Capobianco
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | | | | | - S Ginex
- Biotronik Italia spa, Milano, Italy
| | - N Galie
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| | - M Biffi
- Sant’Orsola-Malpighi Polyclinic, Department of Cardiology, Bologna, Italy
| |
Collapse
|
18
|
Zuffa E, Dardi F, Saia F, Niro F, Palazzini M, Russo V, Taglieri N, Lovato L, De Lorenzis A, Pasca F, Guarino D, Magnani I, Marrozzini C, Manes A, Galie N. Prognostic value of pulmonary artery diameter in patients with pulmonary arterial hypertension. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Pulmonary artery (PA) dilation is common in pulmonary arterial hypertension (PAH) and may cause left main coronary artery (LMCA) compression. This complication have been sistematically evaluated in patients with angina but no evidence is available for patients asymptomatic for angina.
Purpose
To evaluate the prognostic value of PA diameter and the prevalence of LMCA compression in PAH patients with and without angina.
Methods
All patients with PAH and a baseline angio-CT scan were included. The last angio-CT scan performed was considered for PA diameter increase velocity calculation. Patients with angina or radiological signs of suspected LMCA compression underwent a coronary (cor)-CT scan. Patients with a not negative cor-CT underwent invasive coronary angiography. If clinically indicated invasive coronary angiography was performed without a preliminary cor-CT. To evaluate the predictivity for compression at coronary angiography the PA diameter at cor-CT or at the nearest angio-CT scan was considered.
Results
958 patients were included. PA diameter at baseline is higher in patients with congenital heart disease (CHD) and is not predictive of death. The velocity of PA diameter increase is lower in patients with connective tissue disease and is a risk factor for death in both overall population and different etiological subgroups except CHD and pulmonary veno-occlusive disease. 180 patients had angina and 50 had LMCA compression. 120 patients without angina underwent cor-CT and/or coronary angiography and 15 patients had LMCA compression. The best PA diameter cut-offs predicting LMCA compression in symptomatic/asymptomatic patients were, respectively, 40/42 mm (sensitivity and specificity, respectively, 80 and 72%/87 and 77%).
Conclusion
28% of patients with angina and 13% of patients without angina had LMCA compression. We found a similar PA diameter predicting LMCA compression in patients with or without angina. PA diameter, instead, was not predictive of prognosis (maybe because most deaths were related to heart failure and also because patients with LMCA compression were treated with stenting, possibly preventing sudden cardiac death). Eventually, PA diameter velocity increase is associated with prognosis but this may only reflect a severe disease refractory to medical therapy.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- E Zuffa
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Dardi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Saia
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Cardiology, Bologna, Italy
| | - F Niro
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Radiology, Bologna, Italy
| | - M Palazzini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - V Russo
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Radiology, Bologna, Italy
| | - N Taglieri
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Cardiology, Bologna, Italy
| | - L Lovato
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Radiology, Bologna, Italy
| | - A De Lorenzis
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Pasca
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - D Guarino
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - I Magnani
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - C Marrozzini
- Universitary Hospital Sant'orsola Malpighi, Cardio-thoracic-vascular Department, Cardiology, Bologna, Italy
| | - A Manes
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Galie
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| |
Collapse
|
19
|
D'Angelo E, Paolisso P, Foa A, Bergamaschi L, Magnani I, Toniolo S, Donati F, Rinaldi A, Lovato L, Fanti S, Leone O, Rucci P, Pacini D, Galie N, Pizzi C. Diagnostic accuracy of cardiac computed tomography and 18F-fluorodeoxyglucose with positron emission tomography/computed tomography in cardiac masses. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Understanding the nature of cardiac masses represents a challenge for clinicians in order to select the appropriate therapeutic strategies. The diagnostic accuracy of cardiac computed tomography (CT) and 18F-fluorodeoxyglucose (18F-FDG) with positron emission tomography/CT (PET/CT) in identifying the nature of cardiac masses has not been evaluated before in a large population.
Purpose
To assess the diagnostic value of CT and 18F-FDG PET/CT in defining the nature of cardiac masses, integrating morphologic features and metabolic activity.
Methods
Out of 223 we selected a final cohort 60 patients which underwent cardiac CT scan and 18F-FDG PET/CT. All masses had histological certain, apart from thrombi, in which was defined radiologic resolution after adequate anticoagulant treatment. For each mass, eight morphologic CT signs and standardized uptake value (SUVmax, SUVmean), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) in 18F-FDG PET, were evaluated.
Results
Twenty patients had benign cardiac masses and 40 patients malignant cardiac masses. Irregular tumour margins, pericardial effusion, invasions, solid nature of the mass, mass diameter, TC contrast up-take and pre-contrast characteristics were strongly associated with the malignant nature of cardiac masses (p<0.001). Additionally, the presence of at least four CT signs was able to discriminate malignancies, withsensitivity of 95% and specificity of 95% (AUC=0.988, 95% CI 0.969–1). The mean value of SUVmax, SUVmean, MTV and TLG was significantly higher in malignant cardiac masses than in benign lesions (p<0.001). ROC curve for diagnostic accuracy of 18F-FDG PET/CT parameters in detecting malignant lesions showed an excellent performance of SUV (AUC=0.948, 95% CI 0.891–1), MTV (AUC=0.928, 95% CI 0.841–1) and TLG (AUC=0.961, 95% CI 0.902–1).
Conclusions
In patients with cardiac masses, cardiac computed tomography and 18F-FDG PET/CT findings provide independent and incremental prognostic information regarding their nature. A systematic use of CT and 18F-FDG PET/CT is therefore useful for diagnostic and therapeutic purposes.
PET-CT evaluation of cardiac masses
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): S. Orsola Malpighi Hospital, University of Bologna
Collapse
Affiliation(s)
- E.C D'Angelo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Bergamaschi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - I Magnani
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - S Toniolo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - F Donati
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Rinaldi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Lovato
- University Hospital Sant'Orsola, Radiology Unit, Cardio-Thoracic-Vascular Department, S. Orsola Malpighi Hospital, University of Bolo, Bologna, Italy
| | - S Fanti
- Universitary Hospital Sant'Orsola, Institute of Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, Univer, Bologna, Italy
| | - O Leone
- Universitary Hospital Sant'orsola Malpighi, Department of Pathology, University of Bologna, Azienda Ospedaliera S. Orsola-Malpighi of Bologna, I, Bologna, Italy
| | - P Rucci
- Universitary Hospital Sant'orsola Malpighi, Division of Hygiene and Biostatistics, Department of Biomedical and Neuromotor Sciences, Alma Mater, Bologna, Italy
| | - D Pacini
- University Hospital Policlinic S. Orsola-Malpighi, Cardiac Surgery Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Pizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
20
|
Galie N, Sitbon O, Doelberg M, Gibbs J, Hoeper M, Martin N, Mathai S, McLaughlin V, Perchenet L, Simonneau G, Chin K. Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2288] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Long-term outcomes are important in PAH.
Purpose
To evaluate the long-term efficacy and safety of initial triple oral therapy with selexipag, macitentan and tadalafil vs initial double oral therapy with macitentan and tadalafil in PAH.
Methods
TRITON, a multicentre, double-blind, placebo-controlled, phase 3b study, randomised 1:1 newly diagnosed, treatment-naïve PAH patients to initial triple vs double therapy. Macitentan and tadalafil were initiated at randomisation and selexipag/placebo at day 15 (uptitrated to wk 12). Efficacy and safety were assessed in a blinded manner until the last patient randomised completed wk 26 (end of observation period). Pulmonary vascular resistance (PVR; primary endpoint) and 6-minute walk distance (6MWD) were assessed at wk 26. Other secondary endpoints included time to first disease progression event (centrally adjudicated) to end of observation period +7 days. Time to all-cause mortality up to end of observation period was analysed post-hoc.
Results
247 patients were randomised to initial triple (n=123) or initial double therapy (n=124); baseline characteristics were balanced between groups. Median follow-up was 77.6 (initial triple) and 75.8 wks (initial double). Initial triple and initial double therapy improved PVR (by 54% and 52%) and 6MWD (by 55 and 56 m), with no difference between groups. A 41% reduction in the risk of first disease progression event driven by PAH-related hospitalisation and all-cause death was observed with initial triple vs initial double therapy (hazard ratio 0.59, 95% CI 0.32–1.09, p=0.087; Figure). Two patients died in the initial triple vs 9 in the initial double therapy group (hazard ratio 0.23, 95% CI 0.05–1.04). Adverse events were consistent with the known safety profiles of the study drugs.
Conclusions
In TRITON, assessments at wk 26 showed marked improvements in both treatment arms, with no difference between groups. Exploratory analysis indicated a signal for improved long-term outcome with initial triple versus initial double therapy.
Funding Acknowledgement
Type of funding source: Other. Main funding source(s): Actelion Pharmaceuticals Ltd.
Collapse
Affiliation(s)
- N Galie
- University of Bologna, Bologna, Italy
| | - O Sitbon
- Hôpital Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, Paris, France
| | - M Doelberg
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - J.S.R Gibbs
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | - M.M Hoeper
- Hannover Medical School and German Centre for Lung Research, Hannover, Germany
| | - N Martin
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - S.C Mathai
- Johns Hopkins University School of Medicine, Baltimore, United States of America
| | - V McLaughlin
- University of Michigan, Ann Arbor, United States of America
| | - L Perchenet
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - G Simonneau
- Hôpital Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, Paris, France
| | - K Chin
- UT Southwestern Medical Center, Dallas, United States of America
| |
Collapse
|
21
|
De Lorenzis A, Dardi F, Palazzini M, Zuffa E, Pasca F, Guarino D, Magnani I, Rotunno M, Ballerini A, Manes A, Galie N. Prognostic role of comorbidities in patients with pulmonary arterial hypertension. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Epidemiology of pulmonary arterial hypertension (PAH) is changing and the age at diagnosis and the prevalence of comorbidities are increasing but their prognostic relevance is substantially undefined.
Purpose
To evaluate the prognostic value of comorbidities in patients with PAH and in the different clinical subgroups.
Methods
All patients with PAH referred to a single centre underwent baseline right heart catheterization, brain natriuretic peptide (BNP) plasma levels, 6-min walking distance (6MWD), WHO functional class and anamnestic comorbidities evaluation. Cox regression model was used for analysis (p-value <0.1 was considered for inclusion in multivariate analysis).
Results
1311 patients were included [age 51 years; aetiology: 522 idiopathic/heritable/drug-induced (I/H/D)-PAH, 258 connective tissue disease (CTD)-associated PAH, 242 congenital heart disease (CHD)-associated PAH, 196 portal hypertension/HIV (PoHIV)-associated PAH and 93 pulmonary veno-occlusive disease (PVOD)]. 5% of patients have no comorbidities. At multivariate analysis comorbidities independently associated with prognosis are: systemic hypertension in I/H/D [HR 0.616, p=0.030], mean systemic blood pressure in CTD [HR 0.980, p=0.002] and PVOD [HR 0.962, p=0.006], dyslipidemia in CTD [HR 0.447, p=0.001] and PoHIV [HR 0.201, p=0.026], estimated glomerular filtration rate in PoHIV [HR 1.000, p<0.001] and body mass index (BMI) [HR 0.966, p=0.069] in CTD. In CHD comorbidities are not independent determinants of prognosis. Other variables independently predictive of a worse prognosis are: advanced age in all PAH subgroups except PVOD; male gender in I/H/D; reduced 6MWD in I/H/D, CTD and PVOD; high BNP in I/H/D, CHD and PVOD; low cardiac index in CTD, high right atrial pressure in I/H/D and low mixed venous oxygen saturation in CHD.
Conclusion
The age at PAH diagnosis and the prevalence of comorbidities are increasing but their prognostic role seems of poor relevance as we found a protective role of these variables: high systemic blood pressure (maybe indicative of a better haemodynamic stability) in I/H/D, CTD and PVOD; dyslipidemia and high BMI (maybe indicative of a better nutritional status and a less severe autoimmune disease) in CTD; dyslipidemia and a high glomerular filtration rate (both indicative of a less severe liver disease) in PoHIV.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- A De Lorenzis
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Dardi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Palazzini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - E Zuffa
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Pasca
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - D Guarino
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - I Magnani
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Rotunno
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Ballerini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Manes
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Galie
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| |
Collapse
|
22
|
Rosenkranz S, Channick R, Cottreel E, Galie N, Kiely D, Marcus J, Swift A, Tawakol A, Torbicki A, Vonk Noordegraaf A, Wetherill G, Peacock A. Effect of macitentan on left ventricular (LV) function in pulmonary arterial hypertension (PAH): results from REPAIR. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
PAH impacts right ventricular (RV) structure and function but also leads to changes in the LV due to RV/LV interaction and underfilling. REPAIR, the first PAH study to use a primary endpoint assessed by cardiac MRI (cMRI), reported that RV stroke volume (RVSV) increased by 12 mL and pulmonary vascular resistance (PVR) decreased by 38% from baseline (BL) to Week 26 with macitentan.
Purpose
To assess the effect of macitentan on LV function in patients with PAH.
Methods
REPAIR (NCT02310672) was a 52-week, multicentre, open-label, single-arm, phase 4 study assessing the effect of macitentan primarily on RV structure and function, determined by cMRI and right heart catheterisation. Macitentan 10 mg was initiated in treatment-naïve patients, in patients receiving stable background phosphodiesterase type-5 inhibitor (PDE5i) at BL, or in initial combination with PDE5i. Exploratory LV endpoints were assessed by cMRI at Weeks 26 and 52. Safety was assessed up to end of study treatment +30 days in all patients who received ≥1 dose of macitentan (N=87). Patients with BL and Week 26 assessments for both PVR and RVSV were included in the modified Full Analysis Set (mFAS; N=71).
Results
In the mFAS, 57 (80%) patients were female. At BL, median age was 45 years; median (Q1, Q3) six-minute walk distance was 395 (323, 483) m; 48%/51% of patients were WHO functional class II/III; 59% had idiopathic PAH. Compared to BL, at Weeks 26 and 52 there were significant changes in LV cMRI parameters (table). The most common AEs were peripheral oedema (22%), headache (21%) and dizziness (14%).
Conclusions
Macitentan led to improvements in LV mass, volume and function, including clinically-relevant increases in LV stroke volume, at both 26 and 52 weeks in patients with PAH. Safety was consistent with other macitentan clinical trial data.
Funding Acknowledgement
Type of funding source: Other. Main funding source(s): Actelion Pharmaceuticals Ltd
Collapse
Affiliation(s)
- S Rosenkranz
- Heart Center at the University of Cologne, and Cologne Cardiovascular Research Center (CCRC), Cologne, Germany
| | - R Channick
- David Geffen School of Medicine at UCLA, Los Angeles, United States of America
| | - E Cottreel
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - N Galie
- Department of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy
| | - D.G Kiely
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, United Kingdom
| | - J.T Marcus
- Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands (The)
| | - A.J Swift
- Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom
| | - A Tawakol
- Massachusetts General Hospital - Harvard Medical School, Boston, United States of America
| | - A Torbicki
- Department of Pulmonary Circulation CMKP, European Health Center, Otwock, Poland
| | - A Vonk Noordegraaf
- Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands (The)
| | - G Wetherill
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - A Peacock
- Scottish Pulmonary Vascular Unit, Glasgow, United Kingdom
| |
Collapse
|
23
|
Dardi F, Zuffa E, Palazzini M, Pasca F, De Lorenzis A, Guarino D, Magnani I, Ballerini A, Rotunno M, Manes A, Galie N. Short term effect of Selexipag in comparison to parenteral prostacyclin analogues in pulmonary arterial hypertension patients started on double-combination therapy with ERA and PDE-5 inhibitors. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The event-driven, phase 3, randomized, double-blind, placebo-controlled GRIPHON trial demonstrated that Selexipag reduces the risk of a composite end point of death or morbidity events in patients with pulmonary arterial hypertension (PAH). Despite the advantage of a per os formulation, its efficacy in comparison to parenteral prostacyclin analogues in patients already on oral double-combination therapy with endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5-I) is not known.
Purpose
The aim of this study was to compare the effects of Selexipag (S) vs subcutaneous Treprostinil (T) vs intravenous Epoprostenol (E) in PAH patients initially started with double-combination therapy with ERA and PDE5-I.
Methods
We enrolled patients on double combination therapy with ERA + PDE5-I starting S, T or E. Drugs were gradually uptitrated to the maximum tolerated/approved dose. All patients were systematically assessed with WHO-functional class (FC), six minute walk test (6MWT) and right heart catheterization before treatment and 3 months after reaching a stable dose of the drug. Baseline characteristics and changes in 6MWT and haemodynamic parameters were analyzed using Wilcoxon signed-rank test and compared between the 3 drugs with Kruskal-Wallis test.
Results
One hundred and seventy-one patients with PAH were enrolled. Results are shown in the Table. Patients with a complete re-evaluation were 61% of S, 85% of T, 79% with E.
Conclusions
S was prescribed to the oldest and least severe PAH patients. E was prescribed to the youngest and most severe PAH patients and led to the strongest improvement of exercise capacity and haemodynamic profile. T has intermediate characteristics.
Table 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- F Dardi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - E Zuffa
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Palazzini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Pasca
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A De Lorenzis
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - D Guarino
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - I Magnani
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Ballerini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Rotunno
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Manes
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Galie
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| |
Collapse
|
24
|
Rotunno M, Dardi F, De Lorenzis A, Palazzini M, Zuffa E, Pasca F, Guarino D, Magnani I, Ballerini A, Manes A, Galie N. Additional role of echocardiogram in pulmonary arterial hypertension risk stratification according to current ESC/ERS guidelines. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Current pulmonary hypertension (PH) guidelines stratify the risk of patients with pulmonary arterial hypertension (PAH) using a multiparametric approach. A simplified risk table has been recently proposed and validated without including echocardiographic parameters.
Purpose
We evaluate the additional role of echocardiogram in PAH risk stratification using the recently proposed simplified risk table in patients with idiopathic/heritable (I/H) PAH and PAH associated with connective tissue disease (CTD) and congenital heart disease (CHD).
Methods
All patients with I/H-PAH, CTD-PAH and CHD-PAH referred to a single centre were included from 2003 to 2017. All patients were treated according to PH guidelines. The simplified risk assessment considered the following criteria: WHO functional class, 6-min walking distance, right atrial (RA) pressure or brain natriuretic peptide (BNP) plasma levels and cardiac index (CI) or mixed venous oxygen saturation (SvO2). For the last 2 criteria the worst parameter was chosen. Risk strata were defined as: Low risk= at least 3 low risk and no high-risk criteria; High risk= at least 2 high risk criteria including CI or SvO2; Intermediate risk= definitions of low or high risk not fulfilled. Then we performed a Cox analysis to evaluate the independent echocardiographic predictors of survival that were subsequently added to the simplified risk table to test their additional role in ameliorating risk stratification.
Results
461 treatment-naïve patients were enrolled. Echocardiographic independent predictors of prognosis were the severity of tricuspid regurgitation [HR (95% CI) = 1.013 (1.006–1.021); p-value = 0.001], right atrial area [HR (95% CI) = 1.028 (1.012–1.045); p-value = 0.001] and the presence of pericardial effusion [HR (95% CI) = 1.533 (1.142–2.057); p-value= 0.004]. Only RA area significantly ameliorate the risk stratification power of the recently validated simplified PAH risk table (likelihood ratio chi2 increased from 63.8 to 68.1, likelihood ratio test = 0.039). Due to the significant correlation between RA area and both RA pressure (r=0.470; p<0.001) and BNP (r=0.372; p=0.004), we elaborate a second risk table in which RA area (utilizing the cut-offs proposed by the current PH guidelines) was considered together within the criteria including RA pressure and BNP (the worst parameter of the 3 was considered). Considering the second risk table including RA area the risk stratification power significantly improved (likelihood ratio chi2 increased from 63.8 to 72.7, AIC/BIC decreased from 1956/1964 to 1947/1955).
Conclusions
Echocardiographic RA area significantly improve the risk discrimination power of the recently proposed simplified risk table for patients with PAH.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Rotunno
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Dardi
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A De Lorenzis
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - M Palazzini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - E Zuffa
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - F Pasca
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - D Guarino
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - I Magnani
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Ballerini
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - A Manes
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| | - N Galie
- University of Bologna, Department of Specialized, Diagnostic and Experimental Medicine – DIMES - Bologna/IT, Bologna, Italy
| |
Collapse
|
25
|
Vitale G, Di Nicola F, Tanini I, Camporeale A, Graziani F, Ditaranto R, Zanoni R, Ferrara V, Lombardi M, Olivotto I, Rapezzi C, Galie N, Biagini E. Electrocardiographic differences between Anderson-Fabry and sarcomeric hypertrophic cardiomyopathy and correlation with cardiac magnetic resonance. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Differential diagnosis between Anderson-Fabry (AF) and sarcomeric hypertrophic cardiomyopathy (HCM) is often very challenging particularly in AF patients with late onset cardiac involvement.
Purpose
To gain new insights from standard electrocardiogram (ECG) in AF disease for differential diagnosis from sarcomeric HCM. Additionally, to better understand ECG features in AF patients, a correlation substudy ECG-cardiac magnetic resonance (CMR) has been performed.
Methods
From 162 patients with definite diagnosis of AF disease, 111 [65 males, median age 57 (51–67) years] with pathologic left ventricular hypertrophy (LVH) (Group A) were compared with 111 sarcomeric HCM patients (Group B) sex, age and maximal wall thickness matched by 1:1 propensity score.
Results
AF patients showed shorter PR interval [155 (140–180) vs 163 (149–184) msec; p=0.005) and wider QRS interval [110 (100–134) vs 100 (90–106) msec; p<0.0001). Additionally AF patients had a higher prevalence of complete (22% vs 3%; p<0.0001) and incomplete (13% vs 1%; p<0.0001) right bundle branch block (RBBB) and a higher percentage of ST segment depression (12% vs 1%; p=0.001) and inferior negative T waves (34% vs 19%; p=0.01). No differences in terms of Sokolow-Lyon and Cornell scores were found whereas total QRS score was higher in Group A [20 (16–27) vs 18 [14–22] mV; p=0.0004). Low QRS voltages and inferior Q waves were not present in AF patients. Among the 69 AF patients who underwent MRI, the 44 with late gadolinium enhancement (LGE) were older [59 (52–66) vs 53 (40–59) years; p=0.017] and had more frequently negative T waves on ECG, particularly in the inferior leads (64% vs 8%; p<0.0001), compared to the 25 without LGE. At multivariate analysis, age and negative T waves were independently associated to the presence of LGE on CMR.
Conclusions
Compared to matched sarcomeric HCM, AF patients had a shorter PR, wider QRS and a higher percentage of RBBB in relation to to the different aetiology (storage vs “pure” hypertrophy). The higher total QRS score and the absence of inferior Q waves could reflect the more frequent concentric distribution of LVH. Additionally negative T waves, especially in inferior leads, are related to the presence of LGE on CMR (often in the postero-lateral wall).
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- G Vitale
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - F Di Nicola
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - I Tanini
- Careggi University Hospital (AOUC), Cardiomyopathy Unit, Florence, Italy
| | - A Camporeale
- IRCCS Policlinico San Donato, Multimodality Cardiac Imaging Section (A.C., S.P., M.L.), San Donato Milanese, Italy
| | - F Graziani
- Fondazione Policlinico Universitario A. Gemelli IRCSS, Department of Cardiovascular and Thoracic Sciences, Roma, Italy
| | - R Ditaranto
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - R Zanoni
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - V Ferrara
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - M Lombardi
- IRCCS Policlinico San Donato, Multimodality Cardiac Imaging Section (A.C., S.P., M.L.), San Donato Milanese, Italy
| | - I Olivotto
- Careggi University Hospital (AOUC), Cardiomyopathy Unit, Florence, Italy
| | - C Rapezzi
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - N Galie
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| | - E Biagini
- Azienda Ospedaliero, Universitaria di Bologna, Policlinico S.Orsola-Malpigh, Bologna, Italy
| |
Collapse
|
26
|
Paolisso P, Saturi G, Bergamaschi L, D"angelo EC, Coriano M, Foa A, Rinaldi A, Magnani I, Graziosi M, Biagini E, Ferlito M, Pacini D, Pizzi C, Galie N, Rapezzi C. P1248 What are the suspicious echocardiographic features of a malignant cardiac mass? Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Cardiac Masses (CM) represent a rare and heterogeneous group with a prevalence of 0.3% at autopsy, divided in benign masses - primary tumors and pseudotumors - and malignant ones - primitive tumors and metastasis, either directly invading the heart and pericardium or as a consequence of hematologic spread. 2-D Echocardiography is nowadays the first line approach to define nature and management of CM, but is it enough to guide a therapeutic strategy?
PURPOSE
To evaluate echocardiographic CM malignancy features in patients admitted to our Centre between 1997 and 2017.
MATERIALS AND METHODS
We retrospectively evaluated a population of 180 consecutive patients (45% males; mean age 60 ± 16 years; BMI 25 ± 5 Kg/m2), referred to our echocardiographic lab with suspicion CM. All patients were examined in both left lateral and supine position, and heart was visualized from all available echocardiographic windows. Definite diagnosis was obtained by histologic examination of biopsy, surgical samples or, in cases of cardiac thrombi, by radiological evidence of thrombus resolution after adequate anticoagulant treatment. We excluded normal anatomical variants in the group of pseudotumors due to the impossibility of obtaining histological examination. Comparisons between categorical variables were performed by Chi-square or Fisher exact test. P values ≤ 0.05 were considered significant. Variables with statistical signification lower than p ≤ 0.05 in univariable analysis were included in logistic regression analysis to determinate independent predictors of malignant masses.
RESULTS
We detected 129 benign CM (76% primitive tumors and 24% pseudotumors) and 51 malignant cardiac tumors (45% primitive tumors and 55% metastasis). In 7 cases a poor acoustic window did not allow an optimal examination; in remaining 173 patients, the classical 2-D echocardiogram identified 157 masses with a diagnostic accuracy of 91%. Benign tumors and pseudotumours were localized predominantly in left heart chambers, while malignant primitive tumors and metastasis were mainly detected in right heart, in pericardium or in pulmonary artery branches (p < 0.001). The largest ecocardiographic diameter appeared greater for the malignant masses (mean of 49 ± 26 mm) than benign ones (30 ± 16 mm, p = 0.003). The occurrance of any pericardial effusion (p < 0.001), extension to pericardium (p = 0.01) or to main vessels (p = 0.006) were also associated with malignant masses. Finally, multivariate analysis showed only largest diameter (p = 0.001) and pericardial effusion (p < 0.001) were independent predictors of malignancy.
CONCLUSION
2D Echocardiography is an excellent, non invasive technique for first line evaluation of patients with suspicion CM. It is safe, accurate and have high diagnostic accuracy in identifying CM and their benign or malignant nature. In particular, a large mass associated with any pericardial effusion must pose suspect of malignancy.
Collapse
Affiliation(s)
- P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - G Saturi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Bergamaschi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - E C D"angelo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Coriano
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Rinaldi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - I Magnani
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Graziosi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - E Biagini
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Ferlito
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - D Pacini
- University Hospital Policlinic S. Orsola-Malpighi, Cardiac Surgery Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Pizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Rapezzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
27
|
Paolisso P, D"angelo EC, Bergamaschi L, Foa A, Coriano M, Vitale G, Saturi G, Magnani I, Leone O, Pasquale F, Biagini E, Ferlito M, Pizzi C, Rapezzi C, Galie N. P663 Is echocardiogram alone sufficient for cardiac masses characterization? Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Cardiac Masses (CM) represent an heterogeneous group with a prevalence of 0.3% at autopsy, divided in benign masses (primary tumors and pseudotumors) and malignant ones (primitive tumors and metastasis). 2-D Echocardiography is nowadays the first line approach to define nature and management of CM, but is it enough to guide a therapeutic strategy?
PURPOSE
To evaluate echocardiographic diagnosis accuracy for CM in patients admitted to our Centre between 1997 and 2017.
MATERIALS AND METHODS
We retrospectively evaluated a population of 180 consecutive patients (45% males; mean age 60 ± 16 years; BMI 25 ± 5 Kg/m2), referred to our echocardiographic lab with suspicion CM. All patients were examined in both left lateral and supine position, and heart was visualized from all available echocardiographic windows. Definite diagnosis was obtained by histologic examination of biopsy, surgical samples or, in cases of cardiac thrombi, by radiological evidence of thrombus resolution after adequate anticoagulant treatment. We excluded normal anatomical variants in the group of pseudotumors due to the impossibility of obtaining histological examination. Sensitivity, specificity, predictive accuracy for a positive test, and predictive accuracy for a negative test were calculated by standard formulas (corrected for prevalence by Bayes theorem).
RESULTS
We detected 129 benign CM and 51 malignant cardiac tumors. In 7 cases a poor acoustic window did not allow an optimal examination; in remaining 173 patients, the classical 2-D echocardiogram identified 157 masses with a diagnostic accuracy of 91%. Of 173 CM diagnosed, 146 were classified by echocardiographer as benign masses (125 true benign on histological examination) and 27 as malignant ones (all malignant after histological confirmation); the results showed 56% sensitivity, 100% specificity, 100% positive predictive value, 98% negative predictive value, with 88% overall diagnostic accuracy in identifying the nature of masses. 23 cases were undetermined and needed second level instrumental investigations to be characterized. Diagnostic accuracy for distinguishing primary benign tumors and pseudotumors decreased to 80%, with a significant increase in both "false" benign tumors (9 out of 91) and "false" pseudotumors (15 out of 34) with 85% sensitivity, 68% specificity, 10% positive predictive value, 99% negative predictive value.
CONCLUSION
2D Echocardiography is an excellent, non invasive technique for first line evaluation of patients with suspicion CM. It is safe, reliable with a high predictive value and diagnostic accuracy in identifying CM and their benign or malignant nature. In contrast, these results were insufficient to start an anticoagulant in suspicion thrombus or cardiac surgery for primary tumor, since second level instrumental examinations needed. 2D Echocardiography alone seems unuseful for classifying malignant masses in primitive or metastasis.
Collapse
Affiliation(s)
- P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - E C D"angelo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Bergamaschi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Coriano
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - G Vitale
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - G Saturi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - I Magnani
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - O Leone
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - F Pasquale
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - E Biagini
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Ferlito
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Pizzi
- University of Bologna, Bologna, Italy
| | - C Rapezzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
28
|
Bergamaschi L, Stefanizzi A, Coriano M, Paolisso P, Magnani I, Rinaldi A, Saturi G, Foa A, Pomata D, Cavazza M, Caldarera I, Pizzi C, Galie N. P4742Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in newly diagnosed non-valvular atrial fibrillation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Several risk scores have been proposed to assess the bleeding risk in patients with Atrial Fibrillation.
Purpose
To compare the efficacy of HAS-BLED, ATRIA and ORBIT scores to predict major bleedings in newly diagnosed non-valvular AF (NV-AF) treated with vitamin K antagonists (VKAs) or new oral anticoagulants (NOACs).
Methods
We analyzed all consecutive patients with AF at our outpatient clinic from January to December 2017. Only those with new diagnosed NV-AF starting new anticoagulant therapy were enrolled. Major hemorrhagic events were defined according to the ISTH definition in non-surgical patients.
Results
Out of the 820 patients admitted with AF, 305 were newly diagnosed with NV-AF starting oral anticoagulation. Overall, 51.3% were male with a mean age of 72.6±13.7 years. Thirty-six patients (11.8%) started VKAs whereas 269 (88.2%) patients were treated with NOACs. The median follow-up time was 10.4±3.4 months. During follow-up, 123 (32.2%) bleeding events were recorded, 21 (17,1%) in the VKA group and 102 (82,9%) in the NOAC group. Eleven (2.9%) major bleeding events occurred: 5 (45.5%) in the VKA group and 6 (54.5%) in the NOAC group.
Overall, patients with major hemorrhagic events showed a mean value of the scores significantly higher when compared to patients without such bleeding complications (HASBLED 3.4 vs 2.4 p=0.007; ATRIA 5.6 vs 2.4 p<0.001; ORBIT 3.6 vs 1.8 p<0,001). Conversely, when analyzing the VKA subgroup, only the ATRIA score was significantly higher in patients with major adverse events (7.4 vs 3.5 p<0.001; HAS-BLED: 4.4 vs 3.6 p=0.27; ORBIT 4.4 vs 2.9 p=0.13). An ATRIA score ≥4 identified patients at high risk of bleeding (29.4% vs. 0% events. respectively, p=0.04). In the NOAC group, patients with major bleeding events had higher mean values of ATRIA (4.0 vs 2.3 p=0.02) and ORBIT (2.8 vs 1.6 p=0,04) but not the HAS-BLED (2.5 vs 2.3 p=0.57) scores. Similarly, patients on NOACs with an ATRIA score ≥4 had higher rates of major bleedings (8.1% vs. 1.6% p=0,02).
Comparing the single elements of the ATRIA score, only glomerular filtration rate <30 ml/min/1.73 mq was associated with major bleedings in the VKA group (p<0.001) whereas, in the NOAC group, anemia was strongly associated with bleeding events (p=0,02). In fact, multivariate analysis in the NOAC group showed that hemoglobin level at admission was an independent predictor for major bleeding events (OR 0.41, 95% CI 0.23–0.75, P=0.003). Conversely, in the VKA group, baseline creatinine level was an independent predictor for these events (OR 12.76, 95% CI 1.6–101.7, P=0.016).
Conclusions
The ATRIA score showed the best efficacy in predicting major bleeding events. Hemoglobin and creatinine levels at admission were independent predictors for major hemorrhagic events in the NOAC and in the VKA groups, respectively. The latter finding might be helpful in stratifying the hemorrhagic risk at the beginning of treatment.
Collapse
Affiliation(s)
- L Bergamaschi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Stefanizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Coriano
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - I Magnani
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Rinaldi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - G Saturi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - D Pomata
- University Hospital Policlinic S. Orsola-Malpighi, Emergency Department, Bologna, Italy
| | - M Cavazza
- University Hospital Policlinic S. Orsola-Malpighi, Emergency Department, Bologna, Italy
| | - I Caldarera
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Pizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
29
|
Rosenkranz S, Channick R, Chin K, Jenner B, Gaine S, Galie N, Ghofrani HA, Hoeper MM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson V, Lang IM. 4973Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Many PAH patients today have a number of CV comorbidities, yet data on the efficacy and safety of therapies in such patients remain scarce. Most recent PAH clinical trials also include patients with comorbidities.
Purpose
To assess the long-term efficacy and safety of the oral, selective IP prostacyclin receptor agonist, selexipag, in PAH patients with and without significant CV comorbidities using post hoc analysis of GRIPHON data.
Methods
GRIPHON enrolled 1156 PAH patients randomised 1:1 to placebo:selexipag. The present analysis includes patients with right heart catheterisation within 1 year of randomisation who were categorised as with or without CV comorbidities. Patients with CV comorbidities were defined as having ≥3 of the following: body mass index (BMI) >30 kg/m2, history of essential hypertension, diabetes mellitus, or historical evidence of significant coronary artery disease; if PAWP/LVEDP was >12 but <15 mmHg, pulmonary vascular resistance (PVR) had to be >500 dyn.sec/cm5; if PAWP/LVEDP was <12, then PVR had to be >300 dyn.sec/cm5. Selexipag effect on time to first morbidity/mortality (M/M) event up to end of treatment was assessed for both subgroups. Baseline (BL) adjusted treatment hazard ratios with 95% CIs were calculated using Cox models. Model building involved stepwise backward elimination of BL covariates.
Results
752 PAH patients could be categorised based on these criteria (99 with CV comorbidities, 653 without). At BL, patients with CV comorbidities were older (median [range] 60 [28–80] vs 46 [18–78] yrs), had higher BMI (mean [SD] 33.3 [7.23] vs 26.0 [5.64] kg/m2) and lower 6-minute walk distance (mean [SD] 319 [95.7] vs 354 [79.3] m) vs those without. A greater proportion were from Western Europe/Australia/North America (60.6% vs 38.9%) and in WHO functional class III (69.7% vs 49.9%). At BL, 82.8% of patients with CV comorbidities were receiving PAH therapies vs 75.7% of those without. As expected, at BL a higher proportion of patients with CV comorbidities (vs without) had previous/concomitant cardiac disease (62.6% vs 43.0%), metabolism/nutrition disorders (75.8% vs 31.2%), respiratory/thoracic/mediastinal disorders (59.6% vs 37.5%) and vascular disorders (76.8% vs 37.4%). Selexipag reduced the risk of M/M events vs placebo in both subgroups (Figure), with no evidence of an inconsistent treatment effect (interaction p-value=0.1544). Adverse events leading to treatment discontinuation were reported in 35.4% (25.9% selexipag, 46.7% placebo) of patients with CV comorbidities and 35.0% (32.0% selexipag, 38.0% placebo) of those without. Common prostacyclin associated side effects observed with selexipag (headache, diarrhoea, nausea) were reported at a similar incidence in both subgroups.
Conclusions
Selexipag had a beneficial effect on long-term outcome in PAH patients both with and without CV comorbidities. Safety in both groups was consistent with the known profile of selexipag.
Acknowledgement/Funding
Actelion Pharmaceuticals Ltd
Collapse
Affiliation(s)
| | - R Channick
- University of California Los Angeles, Los Angeles, United States of America
| | - K Chin
- UT Southwestern Medical Centre, Dallas, United States of America
| | - B Jenner
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - S Gaine
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - N Galie
- University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Bologna, Italy
| | - H A Ghofrani
- University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center for Lung Research, and Department of Medicine, Imperial College London, London, United Kingdom
| | - M M Hoeper
- Department of Respiratory Medicine, Hannover Medical School and German Center for Lung Research, Hannover, Germany
| | - V V McLaughlin
- University of Michigan, Ann Arbor, United States of America
| | - R Preiss
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - L J Rubin
- Division of Pulmonary and Critical Care Medicine, University of California, San Diego, United States of America
| | - G Simonneau
- Hopital Universitaire de Bicetre, Universite Paris-Sud, Le Kremlin Bicetre, France
| | - O Sitbon
- Hopital Universitaire de Bicetre, Universite Paris-Sud, Le Kremlin Bicetre, France
| | - V Tapson
- Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - I M Lang
- Division of Cardiology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
30
|
D"angelo EC, Guarino D, Vitale G, Foa A, Paolisso P, Coriano M, Di Marco L, Attina D, Lovato L, Russo V, Niro F, Leone O, Pacini D, Pizzi C, Galie N. P460The role of cardiac magnetic resonance in cardiac masses: a single centre experience. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez118.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- E C D"angelo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - D Guarino
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - G Vitale
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - A Foa
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - P Paolisso
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - M Coriano
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - L Di Marco
- University Hospital Policlinic S. Orsola-Malpighi, Cardiac Surgery Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - D Attina
- University Hospital Policlinic S. Orsola-Malpighi, Cardiovascular and Thoracic Department Sant’Orsola- Malpighi , Bologna, Italy
| | - L Lovato
- University Hospital Policlinic S. Orsola-Malpighi, Cardiovascular and Thoracic Department Sant’Orsola- Malpighi , Bologna, Italy
| | - V Russo
- University Hospital Policlinic S. Orsola-Malpighi, Cardiovascular and Thoracic Department Sant’Orsola- Malpighi , Bologna, Italy
| | - F Niro
- University Hospital Policlinic S. Orsola-Malpighi, Cardiovascular and Thoracic Department Sant’Orsola- Malpighi , Bologna, Italy
| | - O Leone
- University Hospital Policlinic S. Orsola-Malpighi, Department of Pathology, Bologna, Italy
| | - D Pacini
- University Hospital Policlinic S. Orsola-Malpighi, Cardiac Surgery Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - C Pizzi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| | - N Galie
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
31
|
D'Angelo E, Guarino D, Vitale G, Foa A, Paolisso P, Coriano M, Di Marco L, Attina D, Lovato L, Russo V, Niro F, Pacini D, Leone O, Pizzi C, Galie N. P703The role of cardiac magnetic resonance imaging in cardiac masses: a single centre experience. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - D Guarino
- University of Bologna, Bologna, Italy
| | - G Vitale
- University of Bologna, Bologna, Italy
| | - A Foa
- University of Bologna, Bologna, Italy
| | | | - M Coriano
- University of Bologna, Bologna, Italy
| | | | - D Attina
- University of Bologna, Bologna, Italy
| | - L Lovato
- University of Bologna, Bologna, Italy
| | - V Russo
- University of Bologna, Bologna, Italy
| | - F Niro
- University of Bologna, Bologna, Italy
| | - D Pacini
- University of Bologna, Bologna, Italy
| | - O Leone
- University of Bologna, Bologna, Italy
| | - C Pizzi
- University of Bologna, Bologna, Italy
| | - N Galie
- University of Bologna, Bologna, Italy
| |
Collapse
|
32
|
Foa A, Vitale G, Paolisso P, Guarino D, D'Angelo E, Coriano M, Martin Suarez S, Bonfiglioli R, Leone O, Pacini D, Fanti S, Pizzi C, Galie N. P704The role of 18FDG PET/TC in addressing cardiac masses malignancy. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Foa
- University of Bologna, Bologna, Italy
| | - G Vitale
- University of Bologna, Bologna, Italy
| | | | - D Guarino
- University of Bologna, Bologna, Italy
| | | | - M Coriano
- University of Bologna, Bologna, Italy
| | | | | | - O Leone
- University of Bologna, Bologna, Italy
| | - D Pacini
- University of Bologna, Bologna, Italy
| | - S Fanti
- University of Bologna, Bologna, Italy
| | - C Pizzi
- University of Bologna, Bologna, Italy
| | - N Galie
- University of Bologna, Bologna, Italy
| |
Collapse
|
33
|
Galie N, Gaine S, Channick R, Ghofrani HA, Hoeper M, Lang I, McLaughlin V, Preiss R, Rubin L, Shiraga Y, Simonneau G, Sitbon O, Tapson V, Chin K. 3016Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- N Galie
- Bologna University Hospital, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna, Italy
| | - S Gaine
- Mater Misericordiae University Hospital, National Pulmonary Hypertension Unit, Dublin, Ireland
| | - R Channick
- Massachusetts General Hospital, Pulmonary and Critical Care, Boston, United States of America
| | - H A Ghofrani
- University of Giessen and Marburg Lung Center (UGMLC) and German Center of Lung Research, Giessen, Germany; Imperial College London, Department of Medicine, London, United Kingdom
| | - M Hoeper
- Hannover Medical School and German Centre for Lung Research, Department of Respiratory Medicine, Hannover, Germany
| | - I Lang
- Medical University of Vienna, Division of Cardiology, Vienna, Austria
| | - V McLaughlin
- University of Michigan Health System, Department of Internal Medicine, Ann Arbor, United States of America
| | - R Preiss
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - L Rubin
- University of California San Diego, Department of Medicine, San Diego, United States of America
| | - Y Shiraga
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - G Simonneau
- Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre and, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Université Paris-Sud, Le Kremlin–Bicêtre; Inserm Unité 999, Le Plessis Robinson, France
| | - O Sitbon
- Assistance Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre and, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Université Paris-Sud, Le Kremlin–Bicêtre; Inserm Unité 999, Le Plessis Robinson, France
| | - V Tapson
- Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - K Chin
- University of Texas Southwestern Medical Center, Dallas, United States of America
| | | |
Collapse
|
34
|
Ghofrani A, Hoeper MM, McLaughlin V, Channick R, Chin K, Delcroix M, Gaine S, Jansa P, Lang I, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, De Souza R, Torbicki A, Tapson V, Perchenet L, Preiss R, Verweij P, Rubin L, Galie N. Pulmonary arterial hypertension-related morbidity is prognostic for survival: Insights from the SERAPHIN and GRIPHON studies. Pneumologie 2018. [DOI: 10.1055/s-0037-1619325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- A Ghofrani
- Med. Klinik II/V, Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen
| | - MM Hoeper
- Klinik für Pneumologie, Zentrum für Innere Medizin, Medizinische Hochschule Hannover
| | - V McLaughlin
- Health System Division of Cardiovascular Medicine, University of Michigan
| | - R Channick
- Massachusetts General Hospital; Harvard Medical School
| | - K Chin
- UT Southwestern Medical Center, Dallas, Texas
| | | | - S Gaine
- Mater Misericordiae Hospital, Dublin, Ireland
| | | | - I Lang
- Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II, Wien
| | - S Mehta
- Lhsc University Hospital, London, Ontario, Canada
| | - T Pulido
- Ignacio Chávez National Heart Institute, Mexico City
| | | | | | - O Sitbon
- Service de Pneumologie, Hôpital Bicêtre, Univ. Paris-Sud
| | - R De Souza
- Incor Heart Institute, University of Sao Paulo
| | | | - V Tapson
- Cedars-Sinai Medical Center, Los Angeles, California
| | - L Perchenet
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - R Preiss
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - P Verweij
- Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
| | - L Rubin
- Division of Pulmonary and Critical Care Medicine University of California; San Diego Medical School
| | - N Galie
- Istituto DI Malattie Dell'apparato Cardiovascolare, Università DI Bologna, Italy
| |
Collapse
|
35
|
Ghofrani A, Benza R, Uno H, Channick R, Delcroix M, Farber H, Galie N, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin L, Sastry BKS, Simonneau G, Sitbon O, De Souza R, Wei LJ, Torbicki A. Using controlled and real-world data in concert to assess survival in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. Pneumologie 2018. [DOI: 10.1055/s-0037-1619326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- A Ghofrani
- Med. Klinik II/V, Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen
| | - R Benza
- Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania
| | - H Uno
- Dana-Farber Cancer Institute, Boston, Massachusetts
| | - R Channick
- Massachusetts General Hospital; Harvard Medical School
| | | | - H Farber
- Boston University School of Medicine
| | - N Galie
- Istituto DI Malattie Dell'apparato Cardiovascolare, Università DI Bologna
| | - B Hennessy
- Actelion Pharmaceuticals Ltd, Allschwi, Switzerland
| | | | - S Mehta
- LHSC University Hospital, London, Ontario
| | - L Perchenet
- Actelion Pharmaceuticals Ltd, Allschwi, Switzerland
| | - T Pulido
- Ignacio Chávez National Heart Institute, Mexico City
| | - D Rosenberg
- Actelion Pharmaceuticals Ltd, Allschwi, Switzerland
| | - L Rubin
- Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School
| | | | | | - O Sitbon
- Service de Pneumologie, Hôpital Bicêtre, Univ. Paris-Sud
| | - R De Souza
- Incor Heart Institute, University of Sao Paulo
| | - LJ Wei
- Harvard University, Boston, Massachusetts
| | | |
Collapse
|
36
|
Galie N, Landzberg M, Beghetti M, Berger R, Efficace M, Gesang S, Papadakis K, Gatzoulis M. P5462Evaluation of macitentan in patients with Eisenmenger syndrome: results from the randomised controlled MAESTRO study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5462] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Sabatino M, Centritto A, Borgese L, Bertolino E, Masetti M, Rinaldi A, Dardi F, Galie N, Grigioni F, Potena L. P445Pulmonary hypertension in patients with advanced heart failure with reduced ejection fraction: a marker but not a maker. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Selby V, Vachiery J, Fang J, Janmohamed M, Klein L, Park M, Benza R, Frantz R, Galie N, De Marco T. The Diastolic Pulmonary Gradient as a Predictor of Adverse Outcomes in Patients With Acute Decompensated Heart Failure. J Heart Lung Transplant 2014. [DOI: 10.1016/j.healun.2014.01.137] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
39
|
|
40
|
Galie N, Channick R, Delcroix M, Ghofrani HA, Jansa P, Le Brun FO, Simonneau G, Rubin LJ. Sustained effect of macitentan, a novel oral endothelin receptor antagonist, on exercise capacity and the association of its measure with long-term outcomes in pulmonary arterial hypertension. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.1061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Jing ZC, Galie N, Ghofrani HA, Humbert M, Langleben D, Rubin LJ, Hoeper MM, Fritsch A, Davie N, Keogh AM. Comparison of hemodynamic parameters in treatment-naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT-1 study. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Galie N, Barst RJ, Oudiz RJ, Li B, Esler A, Simonneau G. Long-term safety and survival outcomes of patients with pulmonary arterial hypertension enrolled in an open label continuation study with tadalafil 40mg daily. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p338] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2013; 35:716-24. [DOI: 10.1093/eurheartj/eht072] [Citation(s) in RCA: 184] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
|
45
|
Rubin LJ, Simonneau G, Badesch D, Galie N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. The study of risk in pulmonary arterial hypertension. Eur Respir Rev 2012; 21:234-8. [DOI: 10.1183/09059180.00003712] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
46
|
Savu C, Petreanu C, Balaita E, Galie N. [Extended lymphadenectomy for left NSLC--case report]. Chirurgia (Bucur) 2012; 107:408-411. [PMID: 22844844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The paper brings up a topical issue in the surgical treatment of non small lung cancer, namely optimal lymphadenectomy for tracking left, considering the anatomical features of specific drainage. This can be achieved by various methods recently introduced in the classical arsenal left lung cancer diagnosis. It's presented in detail a case of extended lymphadenectomy for lung cancer non small left to right paratraheal approach without ligament arterial section. The method allowed a correct staging and reporting of the case more accurate prognosis. The immediate goal of the authors is to discuss on this surgical technique and for long term to achieve a lot with statistical significance in order to assess the value of this method.
Collapse
Affiliation(s)
- C Savu
- Clinica de Chirurgie Toracică I, Institutul de Pneumftiziologie M. Nasta, U.M.E Carol Davila, Bucureşti, Romania
| | | | | | | |
Collapse
|
47
|
Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2011. [DOI: 10.1093/eurheartj/ehr046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Sitbon O, Galie N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev 2010; 19:272-8. [DOI: 10.1183/09059180.00008210] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
49
|
Galie N, Vasile R, Savu C, Petreanu C, Grigorie V, Tabacu E. [Superior vena cava syndrome--surgical solution--case report]. Chirurgia (Bucur) 2010; 105:835-838. [PMID: 21355182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The patient of 52-year-old smoker was admitted in emergency with headaches, dyspnea, oedema and cyanosis of the cephalic extremity and of the superior members. This signs and symptoms suggest a superior vena cava sindrom. Thoracic CT scan shows the thrombosis of the superior vena cava and a tumor localized in the Bariety's Lodge of about 30/40 mm witch is around the right lateral wall of the traheea.This tumor is also tangent to the superior the superior vena cava. The patient was operated by total median sternotomy. By this approach we performed a complete excision of the mediastinal tumor mass. After that we effected a longitudinal cavotomy, we took out the endoluminal clot and we sutured the superior vena cava. The histological diagnosis of the mediastinal tumor was adenocarcinoma tubular-papillary moderately differentiated. The evolution post operative period was favorable the superior vena cava sindrom was a complet remission. The thoracic CT scan control after 9 months later didn't show a local relapse and blood flow was normally throw the superior vena cava.
Collapse
Affiliation(s)
- N Galie
- Secţia de Chirurgie Toracică, Institutul de Pneumologie Marius Nasta Bucureşti.
| | | | | | | | | | | |
Collapse
|
50
|
|